

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 January 2003 (30.01.2003)

PCT

(10) International Publication Number  
**WO 03/007906 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 7/42**,  
C07C 69/618, 69/738, 255/41

(21) International Application Number: PCT/EP02/06743

(22) International Filing Date: 19 June 2002 (19.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/904,904 16 July 2001 (16.07.2001) US  
10/022,343 20 December 2001 (20.12.2001) US

(71) Applicant (for all designated States except US): **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **CHAUDHURI, Ratan, K.** [US/US]; 15 Sherbrooke Drive, Lincoln Park, NJ 07035 (US).

(74) Common Representative: **MERCK PATENT GMBH**; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHOTOSTABLE ORGANIC SUNSCREEN COMPOUNDS WITH ANTIOXIDANT PROPERTIES AND COMPOSITIONS OBTAINED THEREFROM



(57) Abstract: A compound of formula (I) wherein A is a moiety which provides UV absorbing activity to the compound of formula (I) that comprises 2 monovalent groups having carbonyl (C=O) functionality. R<sup>6</sup> is linear or branched C<sub>1</sub>-C<sub>8</sub> alkyl and R<sup>5</sup> is a linear or branched C<sub>1</sub>-C<sub>8</sub>alkyl or hydrogen or linear or branched O-C<sub>1-8</sub>alkyl. Sunscreen formulations which contain these compounds and methods for using these compounds to prepare formulations are also provided.



WO 03/007906 A1

**Photostable organic sunscreen compounds with antioxidant properties and compositions obtained therefrom**

Background of the invention

- 5      Topical sunscreen compositions are commonly used during outdoor work or leisure as a means for providing protection of exposed skin against acute and chronic adverse effects of solar radiation such as sunburn, cancer and photo-aging. Many effective sunscreen preparations are sold commercially or are described in cosmetic or pharmaceutical literature. In
- 10     general sunscreen preparations are formulated as creams, lotions or oils containing as the active agent an ultra violet radiation absorbing chemical compound. The sunscreen functions by blocking passage of ultra violet radiation thereby preventing its penetration into the skin.
- 15     According to Zecchino et al. (US 5,008,100), sunscreen agents may be characterized in the order of decreasing effectiveness as either highly chromophoric (monomeric organic compounds and inorganic compounds such as titanium dioxide) and minimally chromophoric (polymeric organic solids).
- 20     Organic sunscreens are classified into UV-A filters, UV-B filters or broad spectrum filters (UV-A and UV-B functionality in a single molecule) depending on the type of radiation they absorb. UV-A sunscreens absorb radiation in the 320 to 400 nm regions of the ultra violet spectrum and UV-
- 25     B sunscreens absorb radiation in the 290 to 320 nm regions of the ultra violet spectrum. Broad band sunscreens (UV-A and UV-B functionality) absorb radiation in the 290 to 400 nm region of the ultra violet spectrum and have two maximums, one in the UV-B region and the other in the UV-A region.
- 30     Representative references related to UV sunscreens are: US Patent No. 3,278,448, which discloses cinnamic acid derivatives such as 4-hydroxy, 3-5-ditertbutyl-alphacarbethoxy-cinnamic acid ether ester in column 2, line 20; US Patent No. 3,538,226, which describes cinnamic acid alkyl ester derivatives at column 1, lines 15-31 and column 2, lines 1-12 and column
- 35

- 2 -

3, lines 30-55 and 60; US Patent No. 5,175,340, which describes cinnamic acid alkyl esters having hydroxy radicals and alkoxy radicals on the phenyl ring, and US Patent No. 5,830,441, which describes UV absorbents containing a cyano or cinnamyl moiety by the generic formula at col. 2, lines 1-21. Other references which disclose cinnamide compounds include  
5 U.S. Patent Nos. 5,601,811, 4,335,054, 5,124,354, 5,294,643 and 5,514,711.

Unfortunately, some of the highly chromophoric monomeric organic compounds employed in sunscreen compositions are not photostable and  
10 the protection from sun damage is lost. In addition to lack of photostability of many organic sunscreens, they do not possess an antioxidant property which is essential for protecting skin or hair.

The ideal sunscreen formulation should be nontoxic and non-irritating to  
15 the skin tissue and be capable of convenient application in a uniform continuous film. The product should be chemically and physically stable so as to provide an acceptable shelf life upon storage. It is particularly desirable that the preparation should retain its protective effect over a prolonged period after application. Thus, the active agent when present on  
20 the skin must be resistant to chemical and/or photo degradation.


Techniques for stabilizing UV absorbent compositions are known. Representative disclosures in this area include U.S. Patent Nos.  
25 5,567,418, 5,538,716, 5,951,968 and 5,670,140.

It is desirable to provide the antioxidant and photostable sunscreen functionality in a single molecule to enhance the effectiveness of the antioxidant properties.

## 30 SUMMARY OF THE INVENTION


There is provided by the present invention compounds with sunscreen activity, i.e. they are chromophoric within the ultra violet radiation range of  
35 from 290-400 nm and they also exhibit antioxidant properties. These compounds are represented by general formula I

- 3 -



I

In formula I, A is a moiety which provides chromophoric properties within the UV radiation range of 290-400 nm. This moiety comprises two monovalent groups having carbonyl (C=O) functionality. For formula I, each R<sup>6</sup> is independently linear or branched C<sub>1</sub>-C<sub>8</sub> alkyl and R<sup>5</sup> is hydrogen or linear or branched C<sub>1-8</sub> alkyl or linear or branched -O-C<sub>1-8</sub> alkyl. The one or more compounds of formula I can preferably stabilize at least one additional sunscreensing agent against photodegradation from exposure to sunlight. Preferred compounds are of formula II below.



II

For formula II,

R<sup>1</sup> is selected from the group consisting of -C(O)CH<sub>3</sub>, -CO<sub>2</sub>R<sup>3</sup>, -C(O)NH<sub>2</sub> and -C(O)N(R<sup>4</sup>)<sub>2</sub>;

X is O or NH;

R<sup>2</sup> is linear or branched C<sub>1</sub> to C<sub>30</sub> alkyl;

R<sup>3</sup> is linear or branched C<sub>1</sub> to C<sub>20</sub> alkyl;

each R<sup>4</sup> is independently hydrogen or linear or branched C<sub>1</sub> to C<sub>8</sub> alkyl;

R<sup>5</sup> is linear or branched C<sub>1</sub>-C<sub>8</sub> alkyl or hydrogen or linear or branched -O-C<sub>1-8</sub> alkyl, and

R<sup>6</sup> is linear or branched C<sub>1</sub>-C<sub>8</sub> alkyl.


Included within the preferred compounds are those of formula II wherein R<sup>1</sup> is linear or branched C<sub>1</sub>-C<sub>4</sub> alkyl, X is oxygen and R<sup>2</sup> is linear or branched C<sub>1</sub>-C<sub>12</sub> alkyl. Of these compounds, those more preferred have R<sup>1</sup>

- 4 -


as  $C(O)CH_3$  or  $CO_2R^3$  wherein  $R^3$  is a linear or branched  $C_1$  to  $C_4$  alkyl. For compounds wherein  $R^1$  is  $C(O)N(R^4)_2$ ,  $R^4$  is preferably hydrogen or a linear or branched  $C_1$ - $C_4$  alkyl.

5 While compounds having from  $C_1$ - $C_4$  alkyl groups for  $R^2$  and  $R^3$  are preferred, significant utility can be obtained from compounds wherein  $R^2$  and  $R^3$  are linear or branched  $C_8$  to  $C_{20}$  alkyl or  $C_{12}$  to  $C_{20}$  alkyl groups.

10 Another preferred class of compounds are those of formulae III and IV wherein  $R^1$  and  $R^2$  are as defined for formula I with  $R^3$  being  $C_1$ - $C_8$  alkyl and  $R^4$  being  $C_1$ - $C_4$  alkyl.




III




IV

20 In further preferred compounds  $-O-R^6$  and  $-R^5$  are identical. Preferably  $R^5$  is  $-O$ -methyl or  $-O$ -ethyl and  $R^6$  respectively is  $-methyl$  or  $-ethyl$  in these compounds.

25 Another preferred class of compounds are those of formulae V and VI wherein  $R^1$  and  $R^2$  are as defined for formula I with  $R^3$  being  $C_1$ - $C_8$  alkyl and  $R^4$  being  $C_1$ - $C_4$  alkyl.



V



VI

35 Preferred compounds include those selected from the group consisting of ethyl- alpha- cyano-3, 5-dimethoxy- 4-hydroxy cinnamate, ethyl- alpha- acetyl-3, 5-dimethoxy- 4-hydroxy cinnamate,

- 5 -

- iso-propyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy cinnamate,  
iso-amyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy cinnamate,  
2-ethylhexyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy cinnamate,  
diethyl-3, 5-dimethoxy- 4-hydroxy benzylidene malonate,  
di-(2-ethylhexyl)-3,5-dimethoxy- 4-hydroxy benzylidene malonate,  
5 diisoamyl-3, 5-dimethoxy-4-hydroxy benzylidene malonate,  
didodecyl-3,5-dimethoxy-4-hydroxy benzylidene malonate,  
dipalmitoyl-3, 5-dimethoxy-4-hydroxy benzylidene malonate,  
di-isopropyl-3,5-dimethoxy-4-hydroxy benzylidene malonate,  
ethyl- alpha- cyano-3-methoxy- 4-hydroxy cinnamate,  
10 ethyl- alpha- acetyl-3-methoxy- 4-hydroxy cinnamate,  
iso-propyl-alpha-acetyl-3-methoxy-4-hydroxy cinnamate,  
iso-amyl-alpha-acetyl-3-methoxy-4-hydroxy cinnamate,  
2-ethylhexyl-alpha-acetyl-3-methoxy-4-hydroxy cinnamate,  
diethyl-3-methoxy- 4-hydroxy benzylidene malonate,  
15 di-(2-ethylhexyl)-3-methoxy- 4-hydroxy benzylidene malonate,  
diisoamyl-3-methoxy-4-hydroxy benzylidene malonate,  
didodecyl-3-methoxy-4-hydroxy benzylidene malonate,  
dipalmitoyl-3-methoxy-4-hydroxy benzylidene malonate,  
di-isopropyl-3-methoxy-4-hydroxy benzylidene malonate,  
20 di-(2-ethylhexyl)-3-methoxy-4-hydroxy-5-isopropyl-benzylidene malonate,  
di-isoamyl-3-methoxy-4-hydroxy-5-tert.butyl-benzylidene malonate,  
iso-amyl-alpha-acetyl-3-methoxy-4-hydroxy-5-isopropyl cinnamate, and  
iso-amyl-alpha-acetyl-3-methoxy-4-hydroxy-5-tert.butyl cinnamate
- 25 The present invention also provides sunscreen formulations which  
comprise a compound of formula I, II, III and/or IV. These sunscreen  
formulations are effective in absorbing illumination in the range of  
wavelengths of 320 nm and above. Amounts of the compounds of formula  
I, II, III and/or IV within such compositions typically range from 0.1 to 40  
30 wt% based on the total weight of the sunscreen. These sunscreen  
formulations can contain one or more additional organic sunscreen agents  
for filtering UV-B or UV-A rays or they may additionally contain one or  
more metal oxide sunscreen agents such as titanium dioxide or zinc oxide.

35

- 6 -

- These sunscreen formulations may additionally contain a carrier and at least one component selected from the group consisting of dispersing agents, preservatives, anti-foams, perfumes, oils, waxes, propellants, dyes, pigment emulsifiers, surfactants, thickeners, humectants, exfoliants and emollients. These sunscreen formulations may be in the form of a cosmetic composition with a cosmetically acceptable carrier and one or more cosmetic adjuvants. The sunscreen formulation can optionally have conventional antioxidants or other stabilizers which do not have UV absorbing characteristics.
- Methods of using these sunscreen compositions and methods for improving the photostability of sunscreen formulations are also provided. The methods of using the sunscreen formulations comprise applying a sunscreen formulation which contains a compound of formula I, II, III and/or IV to a substrate. Preferred substrates are skin, hair and fibers. To improve the photostability of a sunscreen formulation, a compound of formula I, II, III and/or IV is added to the sunscreen formulation in an amount sufficient to reduce the loss of UV absorbance of the sunscreen as it is irradiated. Typical amounts fall within the range of 0.1% to 40 wt%, based on the total weight of said sunscreen formulation. More typically, the amount falls within the range of 1 wt% to 25 wt%. The amount of organic sunscreen compound of formulae I, II, III and/or IV, preferably ranges from about 3 wt% to about 15 wt% of the sunscreen formulation. Other ingredients referred to above and discussed more particularly below are generally used in an amount from about 0.1 wt% to about 10 wt% of the sunscreen formulation. The balance comprises a cosmetically or pharmaceutically acceptable carrier.
- The sunscreen formulations of this invention preferably offer protection from UV radiation with wavelengths of about 290 nm to 400 nm and preferably from wavelengths in the range of about 290-370 nm. Sunscreen formulations of this invention also typically have a sunscreensing protection factor (SPF) ranging from about 2 to 60, with a preferred SPF range of from about 10 to about 45. The target SPF range can be achieved with a combination of both inorganic and organic chromophoric compounds. SPF is determined by techniques well known in the art, on human skin as

- 7 -

described in the Federal Register, August 25, 1978, Vol. 43, No. 166, pages 38259-38269 (Sunscreen Drug Products for over-the-counter Human Use, Food and Drug Administration). SPF values can also be approximated using in-vitro models as described, for example, in J. Soc. Cosmet. Chem. 44:127-133 (May/June 1989).

5

The sunscreen formulations may contain dispersing agents, emulsifiers or thickening agents to assist in applying a uniform layer of the active compounds. Suitable dispersing agents for the sunscreen formulations include those useful for dispersing organic or inorganic sunscreen agents in either a water phase, oil phase, or part of an emulsion, including, for example, chitosan.

10

Emulsifiers may be used in the sunscreen formulations to disperse one or more of the compounds of formulae I, II, III and/or IV or other component of the sunscreen formulation. Suitable emulsifiers include conventional agents such as, for example, glycerol stearate, stearyl alcohol, cetyl alcohol, dimethicone copolyol phosphate, hexadecyl-D-glucoside, octadecyl-D-glucoside, etc.

15

Thickening agents may be used to increase the viscosity of the sunscreen formulations. Suitable thickening agents include carbomers, acrylate-/acrylonitrile copolymers, xanthan gum and combinations of these. The carbomer thickeners include the crosslinked CARBOPOL® acrylic polymers from B.F. Goodrich. The amount of thickener within the sunscreen formulation, on a solids basis without water, may range from about 0.001 to about 5%, preferably from 0.01 to about 1% and optimally from about 0.1 to about 0.5% by weight.

20

25

Minor optional adjunct ingredients for the sunscreen formulations to be applied to skin or hair may include preservatives, waterproofing agents, fragrances, anti-foam agents, plant extracts (Aloe vera, witch hazel, cucumber, etc) opacifiers, skin conditioning agents and colorants, each in amounts effective to accomplish their respective functions.

30

35



- 8 -

The sunscreen formulations may optionally contain an ingredient which enhances the waterproof properties such as, compounds that form a polymeric film, such as dimethicone copolyol phosphate, diisostearoyl trimethylpropane siloxysilicate, chitosan, dimethicone, polyethylene, polyvinylpyrrolidone (PVP), polyvinylpyrrolidone/vinylacetate,

5

PVP/Eiconsene copolymer and adipic acids/diethylene glycol/glycerine crosspolymer etc. Waterproofing agents may be present at levels of from about 0.01 to about 10% by weight.

10

The sunscreen formulations may also optionally contain one or more skin conditioning agents. These include humectants, exfoliants and emollients.

15

Humectants are polyhydric alcohols intended for moisturizing, reducing scaling and stimulating the removal of built scale from the skin. Typically polyhydric alcohols include polyalkylene glycols and more preferably alkylene polyols and their derivatives. Illustrative are propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, 2-pyrrolidone-5-carboxylate, hydroxypropyl sorbitol, hexylene glycol, ethoxydiglycol 1,3-butylene glycol, 1,2,6-hexanetriol, glycerin, ethoxylated glycerin, propoxylated glycerin and mixtures thereof. Most preferably the humectant is glycerin. Amounts of humectant can range anywhere from 1 to 30%, preferably from 2 to 20% and optimally from about 5 to 10% by weight of the sunscreen composition.

20

25

The exfoliants suitable for use in the present may be selected from alpha-hydroxy carboxylic acids, beta hydroxycarboxylic acids and salts of these acids. Most preferred are glycolic, lactic and salicylic acids and their alkali, metal or ammonium salts.

30

Suitable emollients include those agents known for softening the skin or hair which may be selected from hydrocarbons, fatty acids, fatty alcohols and esters. Petrolatum is a common hydrocarbon type of emollient conditioning agent. Other hydrocarbons that may be employed include alkyl benzoate, mineral oil, polyolefins such as polydecene, and paraffins,

35

such as isohexadecane. Fatty acids and alcohols typically have from about

10 to 30 carbon atoms. Illustrative are myristic, isostearic, hydroxystearic, oleic, linoleic, ricinoleic, behenic and erucic acids and alcohols. Oily ester emollients may be those selected from one or more of the following, triglyceride esters, acetoglyceride esters, ethoxylated glycerides, alkyl esters of fatty acids, ether esters, polyhydric alcohol esters and wax esters. Additional emollients or hydrophobic agents include C<sub>12</sub> to C<sub>15</sub> alkyl benzoate, dioctyladipate, octyl stearate, octyldodecanol, hexyl laurate, octyldodecyl neopentanoate, cyclomethicone, dicapryl ether, dimethicone, phenyl trimethicone, isopropyl myristate, caprylic/capric glycerides, propylene glycol dicaprylate/dicaprate and decyl oleate.

The sunscreen formulations may optionally contain one or more sunscreen agents as discussed above. In principle, all UV filters are suitable for a combination. Particular preference is given to those UV filters whose physiological safety has already been demonstrated. There are many tried and tested substances known from the specialist literature for both UVA and also UVB filters, e.g.

Benzylidenecamphor derivatives, such as

- 3-(4'-methylbenzylidene)-dl-camphor (e.g. Eusolex® 6300),
- 3-benzylidenecamphor (e.g. Mexoryl® SD),
- polymers of N-[(2 and 4)-[(2-oxoborn-3-ylidene)-methyl]benzyl]acrylamide (e.g. Mexoryl® SW),
- N,N,N-trimethyl-4-(2-oxoborn-3-ylidenemethyl)-anilinium methylsulfate (e.g. Mexoryl® SK) or
- alpha-(2-oxoborn-3-ylidene)toluene-4-sulfonic acid (e.g. Mexoryl® SL),

benzoyl- or dibenzoylmethanes, such as

- 1-(4-tert-butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione (e.g. Eusolex® 9020) or
- 4-isopropylidibenzoylmethane (e.g. Eusolex® 8020),

benzophenones, such as

- 2-hydroxy-4-methoxybenzophenone (e.g. Eusolex® 4360) or
- 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt (e.g. Uvinul® MS-40),

- 10 -

4,4,-diarylbutadienes as described in EP-A-0 916 335,

methoxycinnamic esters, such as

- octyl methoxycinnamate (e.g. Eusolex® 2292),
- 5 - isopentyl 4-methoxycinnamate, e.g. as a mixture of the isomers (e.g. Neo Heliopan® 1000),

salicylate derivatives, such as

- 2-ethylhexyl salicylate (e.g. Eusolex® OS),
- 10 - 4-isopropylbenzyl salicylate (e.g. Megasol®) or
- 3,3,5-trimethylcyclohexyl salicylate (e.g. Eusolex® HMS),

4-aminobenzoic acid and derivatives, such as

- 4-aminobenzoic acid,
- 2-ethylhexyl 4-(dimethylamino)benzoate (e.g. Eusolex® 6007),
- 15 - ethoxylated ethyl 4-aminobenzoate (e.g. Uvinul® P25),

diphenylacrylates, e.g. 2-ethylhexyl-2-cyano-3,3-diphenylacrylate (Eusolex® OCR)

- and further substances, such as 2-phenylbenzimidazole-5-sulfonic acid,
- 20 and its potassium, sodium and triethanolamine salts (e.g. Eusolex® 232),
- 3,3'-(1,4-phenylenedimethylene)-bis(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-ylmethanesulfonic acid and its salts (e.g. Mexoryl® SX), 2,4,6-trianilino-(p-carbo-2'-ethylhexyl-1'-oxy)-1,3,5-triazine (e.g. Uvinul® T 150) and 2-(4-Diethylamino-2-hydroxy-benzoyl)-benzoic acid hexyl ester (e.g. Uvinul® A Plus, BASF).
- 25

The compounds given in the list are only to be regarded as examples. It is of course also possible to use other UV filters.

- 30 These organic UV filters are usually incorporated into cosmetic formulations in an amount of from 0.5 to 10% by weight, preferably 1 - 8%.

- Further suitable organic UV filters are, for example, 2-(2H-benzotriazol-2-yl)-4-methyl-6-(2-methyl-3-(1,3,3,3-tetramethyl-1-(trimethylsilyloxy)-disiloxanyl)propyl)phenol (e.g. Silatrizole®), bis(2-ethylhexyl) 4,4'-[(6-[4-
- 35

- 11 -

((1,1-dimethyl-ethyl)---aminocarbonyl)phenylamino]-1,3,5-triazine-2,4-diyl)-  
 diimino]-bis-benzoate (e.g. Uvasorb® HEB), (trimethylsilyl)-  
 [trimethylsilyl]oxy]-poly-[oxy-(dimethyl [and about 6% methyl[2-[p-[2,2-bis-  
 (ethoxycarbonyl]vinyl]phenoxy]-1-methylenethyl] and about 1.5% methyl[3-  
 5 (methyl-hydrogen]silylene]] ( $n \leq 60$ ) (CAS No. 207 574-74-1), 2,2'-  
 methylenebis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol)  
 (CAS No. 103 597-45-1), 2,2'-(1,4-phenylene)bis(1H-benzimidazol-4,6-  
 disulfonic acid, monosodium salt) (CAS No. 180 898-37-7) and 2,4-bis{[4-  
 10 (2-ethylhexyloxy)-2-hydroxyl]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine  
 (CAS No. 103 597-45-, 187 393-00-6).

These organic UV filters are usually incorporated into cosmetic  
 formulations in an amount of from 0.5 to 20% by weight, preferably 1 -  
 15%.

Conceivable as inorganic UV filters are those from the group of titanium  
 dioxides, such as, for example, coated titanium dioxide (e.g. Eusolex® T-  
 2000, Eusolex® T-AQUA), zinc oxides (e.g. Sachtotec®), iron oxides and  
 also cerium oxides. These inorganic UV filters are generally incorporated  
 20 into cosmetic formulations in an amount of from 0.5 to 20% by weight,  
 preferably 2 - 10%.

Preferred compounds with UV-filtering properties are 3-(4'-  
 methylbenzylidene)-dl-camphor, 1-(4-tert-butyl-phenyl)-3-(4-methoxy-  
 25 phenyl)-propane-1,3-dione, 4-iso-propyldi-benzoylmethane, 2-hydroxy-4-  
 methoxy-benzo-phenone, octyl methoxy-cinnamate, 3,3,5-  
 trimethylcyclohexyl salicylate, 2-ethylhexyl 4-(dimethylamino)-benzoate, 2-  
 ethylhexyl 2-cyano-3,3-diphenylacrylate, 2-phenyl-benzimidazole-5-  
 sulfonic acid and its potassium, sodium and triethanolamine salts.

By combining one or more compounds of the formula I with further UV  
 filters it is possible to optimize the protective action against harmful effects  
 of UV radiation.

35

- 12 -

All of the UV filters specified herein including the compounds of formula I can also be used in encapsulated form. In particular, it is advantageous to use organic UV filters in encapsulated form. Specifically, the following advantages arise:

- 5       - The hydrophilicity of the capsule wall can be set independently of the solubility of the UV filter. First, for example, it is possible to incorporate even hydrophobic UV filters into purely aqueous formulations. In addition, the oily impression which is often perceived as unpleasant upon application of the preparation comprising hydrophobic UV filters is prevented.
- 10       - Certain UV filters, in particular dibenzoylmethane derivatives, exhibit only reduced photostability in cosmetic formulations. By encapsulating these filters or compounds which impair the photostability of these filters, such as, for example, the above-mentioned cinnamic acid derivatives, it is possible to increase the photostability of the overall formulation.
- 15       - The literature discusses again and again the penetration of the skin by organic UV filters and the irritancy potential associated therewith upon direct application to the human skin. The encapsulation of the corresponding substances proposed here presents this effect.
- 20       - Generally, by encapsulating individual UV filters or other ingredients, it is possible to avoid formulation problems which arise as a result of interaction of individual formulation constituents with one another, such as crystallization processes, precipitations and agglomeration, since the interaction is prevented.
- 25       It is therefore preferred according to the invention if one or more of the above-mentioned UV filters are present in encapsulated form. In this connection, it is advantageous if the capsules are so small that they can not be observed with the naked eye. To achieve the above-mentioned effects, it is also necessary for the capsules to be sufficiently stable and
- 30       not to release the encapsulated active ingredient (UV filter) into the surroundings, or to release it only to a slight extent.

Suitable capsules can have walls made of inorganic or organic polymers. For example, US 6,242,099 B1 describes the preparation of suitable  
35       capsules with balls made of chitin, chitin derivatives or polyhydroxylated

- 13 -

polyamines. Capsules which are to be used particularly preferably according to the invention have walls which can be obtained by a sol-gel process, as is described in the applications WO 00/09652, WO 00/72806 and WO 00/71084. Preference is given here in turn to capsules whose walls are made of silica gel (silica; undefined silicon oxide hydroxide). The preparation of corresponding capsules is known to the person skilled in the art, for example, from the cited patent applications, the contents of which also expressly belonging to the subject-matter of the present application.

Here, the capsules are present in formulations according to the invention preferably in amounts which ensure that the encapsulated UV filters are present in the formulation in the amounts given above.

The protecting action against oxidative stress or against the effect of free radicals can be further improved if the formulation comprises one or more antioxidants.

There are many tried and tested substances known from the specialist literature which can be used, e.g. amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and derivatives thereof, imidazoles (e.g. urocanic acid) and derivatives thereof, peptides, such as D,L-carnosine, D-carnosine, L-carnosine and derivatives thereof (e.g. anserine), carotinoids, carotenes (e.g.  $\alpha$ -carotene,  $\beta$ -carotene, lycopene) and derivatives thereof, chlorogenic acid and derivatives thereof, lipoic acid and derivatives thereof (e.g. dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and the glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl,  $\alpha$ -linoleyl, cholesteryl and glycerylestere thereof), and salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts), and sulfoximine compounds (e.g. buthionine-sulfoximine, homocysteine-sulfoximine, buthionine-sulfone, penta-, hexa- and heptathionine-sulfoximine) in very low tolerated doses (e.g. pmol to  $\mu$ mol/kg), and also (metal) chelating agents, (e.g.  $\alpha$ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin),  $\alpha$ -hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin,

- 14 -

EDTA, EGTA and derivatives thereof, unsaturated fatty acids and derivatives thereof, vitamin C and derivatives (e.g. ascorbyl palmitate, magnesium ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate), vitamin A and derivatives (e.g. vitamin A palmitate), and coniferyl benzoate of benzoin resin, rutin and salts of the sulfuric ester of rutin and derivatives thereof,  $\alpha$ -glycosyl rutin, ferulic acid, 5 furfurylidineglucitol, carosine, butylhydroxy-toluene, butylhydroxyanisol, nordihydroguarectic acid, trihydroxybutyrophenone, quercetin, uric acid and derivatives thereof, mannose and derivatives thereof, zinc and derivatives thereof (e.g. ZnO, ZnSO<sub>4</sub>), selenium and derivatives thereof (e.g. seleno- 10 methionine), stilbenes and derivatives thereof (e.g. stilbene oxide, trans-stilbene oxide).

Mixtures of antioxidants are likewise suitable for use in the cosmetic formulations according to the invention. Known and commercial mixtures 15 are, for example, mixtures comprising, as active ingredients, lecithin, L-(+)-ascorbyl palmitate and citric acid (e.g. Oxydex® AP), natural tocopherols, L-(+)-ascorbyl palmitate, L-(+)-ascorbic acid and citric acid (e.g. Oxydex® K LIQUID), tocopherol extracts from natural sources, L-(+)-ascorbyl palmitate, L-(+)-ascorbic acid and citric acid (e.g. Oxydex® L LIQUID), DL- 20  $\alpha$ -tocopherol, L-(+)-ascorbyl palmitate, citric acid and lecithin (e.g. Oxydex® LM) or butylhydroxytoluene (BHT), L-(+)-ascorbyl palmitate and citric acid (e.g. Oxydex® 2004).

The formulations according to the invention can comprise vitamins as 25 further ingredients. Preferably, vitamins and vitamin derivatives chosen from vitamin A, vitamin A propionate, vitamin A palmitate, vitamin A acetate, retinol, vitamin B, thiamine chloride hydrochloride (vitamin B1), riboflavin (vitamin B2) nicotinamide, vitamin C (ascorbic acid), vitamin D, ergocalciferol (vitamin D2), vitamin E, DL-tocopherol, tocopherol E acetate, 30 tocopherol hydrogen-succinate, vitamin K1, esculin (vitamin P active ingredient), thiamine (vitamin B1) nicotinic acid (niacin), pyridoxine, pyridoxal, pyridoxamine, (vitamin B6), panthothenic acid, biotin, folic acid and cobalamine (vitamin B12) are present in the cosmetic formulations according to the invention, particularly preferably vitamin A palmitate, 35

- 15 -

vitamin C, DL-tocopherol, tocopherol E acetate, nicotinic acid, panthothenic acid and biotin.

The composition of our invention can be a cosmetic formulation or a pharmaceutical formulation.

5

Examples of application forms of the cosmetic or pharmaceutical formulations according to the invention which may be mentioned are: solutions, suspensions, emulsions, PIT emulsions, pastes, ointments, gels, creams, lotions, powders, soaps, foams, surfactant-containing cleansing preparations, oils, aerosols and sprays. Examples of other application forms are sticks, shampoos and shower preparations. Any customary carriers, auxiliaries and optionally further active ingredients may be added to the formulation.

10

15

Preferred auxiliaries originate from the group of preservatives, antioxidants, stabilizers, solubility promoters, vitamins, colorants, odour improvers.

20

Ointments, pastes, creams and gels may comprise the customary carriers, e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc and zinc oxide or mixtures of these substances.

25

Powders and sprays may comprise the customary carriers, e.g. lactose, talc, silica, aluminium hydroxide, calcium silicate and polyamide powder or mixtures of these substances. Sprays can additionally comprise customary propellants, e.g. chlorofluorocarbons, propane/butane or dimethyl ether.

30

Solutions and emulsions can comprise the customary carriers, such as solvents, solubility promoters and emulsifiers, e.g. water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol, oils, in particular cotton seed oil, peanut oil, wheatgerm oil, olive oil, castor oil and sesame oil, glycerol fatty acid ester, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances.

35



Suspensions can comprise the customary carriers such as liquid diluents, e.g. water, ethanol or propylene glycol, suspending agents, e.g. ethoxylated isostearyl alcohols, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar agar and tragacanth or mixtures of these substances.

Soaps can comprise the customary carriers, such as alkali metal salts of fatty acids, salts of fatty acid mono esters, fatty acid protein hydrolysates, isethionates, lanolin, fatty alcohol, vegetable oils, plant extracts, glycerol, sugars or mixtures of these substances.

Surfactant-containing cleansing products can comprise the customary carrier substances, such as salts of fatty alcohol sulfates, fatty alcohol ether sulfates, sulfosuccinic monoesters, fatty acid protein hydrolysates, isethionates, imidazolinium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable and synthetic oils, lanolin derivatives, ethoxylated glycerol fatty acid esters or mixtures of these substances.

Face and body oils can comprise the customary carrier substances such as synthetic oils, such as fatty acid esters, fatty alcohols, silicone oils, natural oils, such as vegetable oils and oily plant extracts, paraffin oils, lanolin oils or mixtures of these substances.

Further typically cosmetic application forms are also lipsticks, lipcare sticks, mascara, eyeliner, eyeshadow, blusher, powder make-up, emulsion make-up and wax make-up, and sunscreen, presun and aftersun preparations.

All compounds or components which can be used in the cosmetic formulations are either known and available commercially or can be synthesized by known processes.

- 17 -

As dispersant or solubilizer it is possible to use an oil, wax or other fatty substance, a lower monoalcohol or a lower polyol or mixtures thereof. Preferred monoalcohols or polyols include ethanol, isopropanol, propylene glycol, glycerol and sorbitol.

5 A preferred embodiment of the invention is an emulsion in the form of a protective cream or milk and which comprise, for example, fatty alcohols, fatty acids, fatty acid esters, in particular triglycerides of fatty acids, lanolin, natural and synthetic oils or waxes and emulsifiers in the presence of water.

10 Further preferred embodiments are oily lotions based on natural or synthetic oils and waxes, lanolin, fatty acid esters, in particular triglycerides of fatty acids, or oily-alcoholic lotions based on a lower alcohol, such as ethanol, or a glycerol, such as propylene glycol, and/or a polyol, such as  
15 glycerol, and oils, waxes and fatty acid esters, such as triglycerides of fatty acids.

The cosmetic preparation according to the invention can also be in the form of an alcoholic gel which comprises one or more lower alcohols or  
20 polyols, such as ethanol, propylene glycol or glycerol, and a thickener, such as siliceous earth. The oily-alcoholic gels also comprise natural or synthetic oil or wax.

Preferred compositions of our invention are hydrogels. The hydrophilicity of  
25 the capsule wall can be set independently of the solubility of the UV filter. For example, it is possible to incorporate even hydrophobic UV filters into purely aqueous formulations. Due to this possibility to include high amounts of hydrophobic UV filters in encapsulated or immobilized form, as described above, those hydrogels of our inventions can posses high SPF  
30 values, in a range normally only acheived with oily formulations.

The solid sticks consist of natural or synthetic waxes and oils, fatty alcohols, fatty acids, fatty acid esters, lanolin and other fatty substances.

35

- 18 -

All compounds or components which can be used in the cosmetic or pharmaceutical formulations are either known and available commercially or can be synthesized by known processes.

5 The composition according to the invention is particularly suitable for protecting human skin against the harmful influences of the UV constituents in sunlight, in addition they also offer protection against ageing processes of the skin and against oxidative stress, i.e. against damage caused by free radicals, as are produced, for example, by solar irradiation, heat or other influences.

10 Therefore the use of a composition according to our invention for the manufacture of a medicament suitable for the prophylaxis of damages of the skin caused by sunray, especially for the prophylaxis of sunburn and sun-caused erythrema is another embodiment of our invention. A further  
15 embodiment is the cosmetic prophylaxis of damages of the skin caused by sunray, especially for the prophylaxis of sunburn and sun-caused erythrema.

20 The formulation may comprise adjuvants which are customarily used in this type of composition, such as, for example, thickeners, softeners, moisturizers, surface-active agents, emulsifiers, preservatives, perfumes, waxes, lanolin, propellants, dyes and/or pigments which colour the composition itself or the skin, and other ingredients customarily used in cosmetics.

25 The composition may be a foamable composition able to be foamed up with or without an propellant. According to our invention it is especially preferred if the foam is produced without the use of a organic propellant. Sprays using organic propellents may not be stored in direct sun or at  
30 higher temperatures; conditions that for example can often be found on the beach during summer. An advantage of preferred compositions according to our invention is that the may be stored and used even under these conditions.

35

- 19 -

Preferred compositions are included in a foam dispenser, preferably in a foam dispenser that requires no organic propellant as described above.

5 As foam builders / stabilisers in general all substances able to build or stabilise a foam may be used. Those substances in general are known to those skilled in the art. Preferred foam builders / stabilisers are those which are skin tolerant or even more preferably give a benefit to the skin.

10 The foam builders / stabilisers are usually present in an amount of about 0.01 to 20 % by weight, preferably in an amount of 0.1 to 5 % by weight and even more preferred in an amount of 0.1 to 3 % by weight.

15 Preferred foam builders / stabilisers are cetyl phosphate, DEA cetyl phosphate, TEA myristate, TEA stearate, magnesium stearate, sodium stearate, potassium laurate, potassium ricinoleate, sodium cocoate, sodium tallowate, potassium castorate, sodium oleate and mixtures thereof.

20 Other preferred foam stabilisers are so called foam boosters. Foam boosters are substances which increase the surface viscosity of the liquid which surrounds the individual bubbles in a foam. These agents are commonly used in shaving soaps, shampoos, bubble baths, liquid soaps, mousses, or aerosol-dispensed foams. Also Film Formers or Viscosity-Increasing Agents maybe used as foam boosters. The listing below gives examples for foam boosters which can also be classified as surfactants (INCI names):

30 Acetamide MEA, Almondamide DEA, Almondamidopropylamine Oxide, Almondamidopropyl Betaine, Apricotamide DEA, Apricotamidopropyl Betaine, Avocadamide DEA, Avocadamidopropyl Betaine, Babassuamide DEA, Babassuamidopropylamine Oxide, Babassuamidopropyl Betaine, Behenamide DEA, Behenamide MEA, Behenamidopropyl Betaine, Behenamine Oxide, Behenyl Betaine, Canolamidopropyl Betaine, Capramide DEA, Carnitine, Cetearyl Alcohol, Cetyl Alcohol, Cetyl Betaine, Cocamide DEA, Cocamide MEA, Cocamide MIPA, Cocamidoethyl

35 Betaine, Cocamidopropylamine Oxide, Cocamidopropyl Betaine,

- 20 -

Cocamidopropyl Hydroxysultaine, Cocamine Oxide, Cocoamphodi-  
 propionic Acid, Cocobetainamido Amphopropionate, Coco-Betaine, Coco-  
 Hydroxysultaine, Coco-Morpholine Oxide, Coconut Alcohol,  
 Coco/Oleamidopropyl Betaine, Coco-Sultaine, Cocoyl Sarcosinamide  
 5 DEA, DEA-Cocoamphodipropionate, DEA-Lauraminopropionate, Decyl  
 Alcohol, Decylamine Oxide, Decyl Betaine, Diethanolaminooleamide DEA,  
 Dihydroxyethyl C8-10 Alkoxypropylamine Oxide, Dihydroxyethyl C9-11  
 Alkoxypropylamine Oxide, Dihydroxyethyl C12-15 Alkoxypropylamine  
 Oxide, Dihydroxyethyl Cocamine Oxide, Dihydroxyethyl Lauramine Oxide,  
 10 Dihydroxyethyl Stearamine Oxide, Dihydroxyethyl Tallowamine Oxide,  
 Dimethicone Propyl PG-Betaine, Disodium Caproamphodiacetate,  
 Disodium Caproamphodipropionate, Disodium Capryloamphodiacetate,  
 Disodium Capryloamphodipropionate, Disodium Cetearyl  
 Sulfosuccinate Disodium Cocamido MIPA-Sulfosuccinate, Disodium  
 Cocamido PEG-3 Sulfosuccinate, Disodium Cocaminopropyl  
 15 Iminodiacetate, Disodium Cocoamphocarboxyethylhydroxypropylsulfonate,  
 Disodium Cocoamphodiacetate, Disodium Cocoamphodipropionate,  
 Disodium C12-15 Pareth Sulfosuccinate, Disodium Deceth-5  
 Sulfosuccinate, Disodium Deceth-6 Sulfosuccinate, Disodium  
 Hydrogenated Cottonseed Glyceride Sulfosuccinate, Disodium Isodecyl  
 20 Sulfosuccinate, Disodium Isostearamido MEA-Sulfosuccinate, Disodium  
 Isostearamido MIPA-Sulfosuccinate, Disodium Isostearoamphodiacetate,  
 Disodium Isostearoamphodipropionate, Disodium Isostearyl  
 Sulfosuccinate, Disodium Laneth-5 Sulfosuccinate, Disodium Lauramido  
 MEA-Sulfosuccinate, Disodium Lauramido PEG-2 Sulfosuccinate,  
 25 Disodium Laureth-5 Carboxyamphodiacetate, Disodium Laureth  
 Sulfosuccinate, Disodium Laureth-6 Sulfosuccinate, Disodium Laureth-9  
 Sulfosuccinate, Disodium Laureth-12 Sulfosuccinate, Disodium  
 Lauroamphodiacetate, Disodium Lauroamphodipropionate, Disodium Lauryl  
 Sulfosuccinate, Disodium Myristamido MEA-Sulfosuccinate, Disodium  
 30 Nonoxynol-10 Sulfosuccinate, Disodium Oleamido MEA-Sulfosuccinate,  
 Disodium Oleamido MIPA-Sulfosuccinate, Disodium Oleamido PEG-2  
 Sulfosuccinate, Disodium Oleoamphodipropionate, Disodium Oleth-3  
 Sulfosuccinate, Disodium Oleyl Sulfosuccinate, Disodium Palmitamido  
 PEG-2 Sulfosuccinate, Disodium Palmitoleamido PEG-2 Sulfosuccinate,  
 35 Disodium PEG-4 Cocamido MIPA-Sulfosuccinate, Disodium PPG-2-

- 21 -

Isodeceth-7 Carboxyamphodiacetate, Disodium Ricinoleamido MEA-Sulfosuccinate, Disodium Stearamido MEA-Sulfosuccinate, Disodium Stearoamphodiacetate, Disodium Stearyl Sulfosuccinamate, Disodium Stearyl Sulfosuccinate, Disodium Tallamido MEA-Sulfosuccinate, Disodium Tallowamido MEA-Sulfosuccinate, Disodium  
 5 Tallowamphodiacetate, Disodium Tallow Sulfosuccinamate, Disodium Tridecylsulfosuccinate, Disodium Undecylenamido MEA-Sulfosuccinate, Disodium Undecylenamido PEG-2 Sulfosuccinate, Disodium Wheat Germamido MEA-Sulfosuccinate, Disodium Wheat Germamido PEG-2 Sulfosuccinate, Disodium Wheatgermamphodiacetate, Di-TEA-Oleamido  
 10 PEG-2 Sulfosuccinate, Ditridecyl Sodium Sulfosuccinate, Erucamidopropyl Hydroxysultaine, Hydrogenated Tallow Alcohol, Hydrogenated Tallowamide DEA, Hydrogenated Tallowamine Oxide, Hydrogenated Tallow Betaine, Hydroxyethyl Carboxymethyl Cocamidopropylamine, Hydroxyethyl Hydroxypropyl C12-15 Alkoxypropylamine Oxide,  
 15 Hydroxystearamide MEA, Isostearamide DEA, Isostearamide MEA, Isostearamide MIPA, Isostearamidopropylamine Oxide, Isostearamidopropyl Betaine, Isostearamidopropyl Morpholine Oxide, Lactamide MEA, Lanolinamide DEA, Lauramide DEA, Lauramide MEA, Lauramide MIPA, Lauramide/Myristamide DEA, Lauramidopropylamine Oxide, Lauramidopropyl Betaine, Lauramine Oxide, Lauroampho-dipropionic Acid, Lauryl Alcohol, Lauryl Betaine, Lauryl Hydroxysultaine, Lauryl Sultaine,  
 20 Lecithinamide DEA, Linoleamide DEA, Linoleamide MEA, Linoleamide MIPA, Methyl Morpholine Oxide, Minkamide DEA, Minkamidopropylamine Oxide, Minkamidopropyl Betaine, Myristamide DEA, Myristamide MEA, Myristamide MIPA, Myristamidopropylamine Oxide, Myristamidopropyl Betaine, Myristamine Oxide, Myristaminopropionic Acid, Myristyl Alcohol, Myristyl Betaine, Myristyl/Cetyl Amine Oxide, Oleamide DEA, Oleamide MEA, Oleamide MIPA, Oleamidopropylamine Oxide, Oleamidopropyl Betaine, Oleamidopropyl Hydroxysultaine, Oleamine Oxide, Oleyl Betaine,  
 25 Olivamide DEA, Olivamidopropylamine Oxide, Olivamidopropyl Betaine, Palmamide DEA, Palmamide MEA, Palmamide MIPA, Palmamidopropyl Betaine, Palmitamide DEA, Palmitamide MEA, Palmitamidopropylamine Oxide, Palmitamidopropyl Betaine, Palmitamine Oxide, Palm Kernel Alcohol, Palm Kernelamide DEA, Palm Kernelamide MEA, Palm  
 35 Kernelamide MIPA, Palm Kernelamidopropyl Betaine, Peanutamide MEA,

- 22 -

Peanutamide MIPA, PEG-3 Cocamide, PEG-2 Hydrogenated Tallow  
Amine, PEG-3 Lauramide, PEG-3 Lauramide Oxide, PEG-2 Oleamide,  
PEG-3 Oleamide, PEG-2 Oleamine, PEG-2 Soyamine, PEG-2  
Stearamine, Potassium Dihydroxyethyl Cocamine Oxide Phosphate,  
Ricinoleamide DEA, Ricinoleamide MEA, Ricinoleamide MIPA,  
5 Ricinoleamidopropyl Betaine, Sesamide DEA, Sesamidopropylamine  
Oxide, Sesamidopropyl Betaine, Sodium Caproamphoacetate, Sodium  
Caproamphohydroxy-propylsulfonate, Sodium Caproamphopropionate,  
Sodium Capryloampho-acetate, Sodium Capryloamphohydroxypropyl-  
sulfonate, Sodium Capryloamphopropionate, Sodium Cocoamphoacetate,  
10 Sodium Cocoamphohydroxypropylsulfonate, Sodium Cocoampho-  
propionate, Sodium Cornamphopropionate, Sodium Isostearoampho-  
acetate, Sodium Isostearoamphopropionate, Sodium Lauramidopropyl  
Hydroxyphostaine, Sodium Lauraminopropionate, Sodium  
Lauriminodipropionate, Sodium Lauroamphoacetate, Sodium/MEA  
15 Laureth-2 Sulfosuccinate, Sodium Myristoamphoacetate, Sodium  
Oleoamphoacetate, Sodium Oleoampho-hydroxy-propylsulfonate, Sodium  
Oleoamphopropionate, Sodium Ricinoleoamphoacetate, Sodium  
Stearoamphoacetate, Sodium Stearoamphohydroxypropylsulfonate,  
Sodium Stearoamphopropionate, Sodium Tallamphopropionate, Sodium  
20 Tallowamphoacetate, Sodium Tallowate, Sodium Undecylenoampho-  
acetate, Sodium Undecylenoampho-propionate, Sodium Wheat  
Germamphoacetate, Soyamide DEA, Soyamidopropyl Betaine,  
Stearamide AMP, Stearamide DEA, Stearamide DEA-Distearate,  
Stearamide MEA, Stearamide MEA-Stearate, Stearamide MIPA,  
25 Stearamidopropylamine Oxide, Stearamidopropyl Betaine, Stearamine  
Oxide, Stearyl Alcohol, Stearyl Betaine, Tallamide DEA, Tallowamide DEA,  
Tallowamide MEA, Tallowamidopropylamine Oxide, Tallowamidopropyl  
Betaine, Tallowamidopropyl Hydroxysultaine, Tallowamine Oxide, Tallow  
Betaine, TEA-Lauraminopropionate, TEA-Myristaminopropionate,  
30 Trideceth-2 Carboxamide MEA, Trisodium Lauroampho PG-Acetate  
Phosphate Chloride, Undecylenamide DEA, Undecylenamide MEA,  
Undecylenamidopropylamine Oxide, Undecylenamidopropyl Betaine,  
Wheat Germamide DEA, Wheat Germamidopropylamine Oxide, Wheat  
Germamidopropyl Betaine.

35

- 23 -

In another embodiment at least one foam builder / stabiliser is selected from foaming surfactants, preferably from alkylglycosides, anionic protein derivatives or fatty acid sulfonates.

5 An especially preferred foam builder / stabilisers are anionic protein derivatives, such as lipoaminoacids described in WO 98/09611, WO 99/27902 and WO 99/45899. Most preferred under these anionic protein derivatives are sodium lauroyl oat amino acids, for example known as Proteol™ Oat (Tradename of Seppic).

10 The cosmetic formulation can also be used to protect the hair against photochemical damage in order to prevent changes of colour shades, decoloration or damage of a mechanical nature. In this case, a suitable formulation is in the form of a shampoo or lotion for rinsing out, the formulation in question being applied before or after shampooing, before  
15 or after colouring or bleaching or before or after permanent waving. It is also possible to choose a formulation in the form of a lotion or gel for styling or treating the hair, in the form of a lotion or gel for brushing or blow-waving, in the form of a hair lacquer, permanent waving composition, colorant or bleach for the hair. The cosmetic formulation may comprise  
20 various adjuvants used in this type of composition, such as surface-active agents, thickeners, polymers, softeners, preservatives, foam stabilizers, electrolytes, organic solvents, silicone derivatives, antigrease agents, dyes and/or pigments which colour the composition itself or the hair, or other ingredients customarily used for hair care.

25 To protect the skin and/or natural or sensitized hair against solar rays, the cosmetic composition is applied to the skin or the hair. Sensitized hair is understood here as meaning hair which has been subjected to a chemical treatment, such as a permanent waving treatment, a colouring process or  
30 bleaching process.

Sunscreen formulations of this invention as described in Formulations 1-16 can be prepared by conventional means.

35



- 24 -

## Formulation 1

	<u>Phase A</u>		<u>Phase B</u>	
	Deionized water	60.0 %	Ethyl-alpha-acetyl-3, methoxy-4-hydroxy cinnamate	8.75 %
5	Disodium EDTA	0.10 %	Octyl salicylate	5 %
	Glycerin	1.5 %	Aluminum stearate	5 %
	NaCl	3.0 %	Cyclomethicone/dimethicone	10 %
	Butylene glycol	2.5 %	Cetyl dimethicone	1 %
			Cyclomethicone	2 %
10			ABIC- EM 97	1 %
			Fragrance	15 %

## Procedure:

15 Combine phase B ingredients. Stir and heat to 70-75°C. Combine Phase A ingredients. Heat while stirring to 70-75°C. Add Phase B to Phase A while stirring. Add preservative. Stir, allowing mixture to cool to room temperature.

20

25

30

35

- 25 -

## Formulation 2: Sunscreen Oil/Water Spray Lotion

	INCI Name	Trade Name (Supplier)	% w/w
	<b>Phase A-1</b>		
5	Di-isopropyl-3-methoxy-4-hydroxybenzylidene malonate		7.50
	Benzophenone-3	Eusolex® 4360 (Rona)	2.50
	Dicapryl ether	Cetiol® OE (Henkel)	4.50
	Dimethicone	Dow Corning 200®, 50 cst (Dow)	2.00
	Stearyl Alcohol	Crodacol S-70 (Croda)	0.60
10	PPG-2 Cetareth-9	Eumulgin® L (Henkel)	0.40
	Steareth-10	Volpo 10 (Croda)	0.50
	Glyceryl stearate, PEG-100 Stearate	Arlacel® 165 (ICI)	2.80
	<b>Phase A-2</b>		
	Titanium Dioxide, Simethicone, Alumina	Eusolex® T-2000 (Rona)	5.00
	<b>Phase B-1</b>		
15	Demineralized water		66.10
	Chitosan, water	Hydagen® CMF (Henkel)	2.00
	Glycerin USP	Emery 916 (Henkel)	2.50
	Dimethicone copolyol phosphate	Pecosil PS-100 (Phoenix Chemical)	2.50
	<b>Phase B-2</b>		
20	Polyquaternium 37, Mineral oil, PPG-1 trideceth-6	Salcare SC 95 (Ciba)	0.40
	<b>Phase C</b>		
	Propylene Glycol, DMDM Hydantoin, Methylparaben, Propylparaben	Paragon™ II (McIntyre)	0.70
	<b>Total</b>		<b>100.00</b>

## 25 Procedure

Combine A-1; stir and heat to 60°C until all solids are dissolved. Disperse A-2 in A-1 with agitation. Combine B-1; stir and heat to 60°C. Disperse B-2 in B-1 with agitation. Add A to B while stirring vigorously. Gently homogenize allowing mixture to cool to 40°C. Add C to A/B: gently homogenize until mixture is uniform. Stir with anchor mixer allowing mixture to reach 25°C prior to packaging. Use a high shear pump spray device for dispensing (e.g., Eurogel pump by Seaquist Perfect)

35

- 26 -

## Formulation 3: Sunscreen Cream

	INCI Name	Trade Name/Manufacturer	% w/w
	<b>Phase A</b>		
5	Deionized water		39.73
	Carbomer (2% aq. solution)	Carbopol 980/BF Goodrich	15.00
	Propylene Glycol		5.00
	Methylparaben		0.20
	Propylparaben		0.10
10	Triethanolamine (99%)		0.45
	Tetrasodium EDTA		0.02
	<b>Phase B</b>		
	Octyl Methoxycinnamate	Eusolex® 2292/Rona	5.00
	Benzophenone-3	Eusolex® 44360/Rona	3.00
15	Di-isoamyl-3-methoxy-4-hydroxybenzylidene malonate		4.50
	Glyceryl Stearate (and) PEG-100 Stearate	Ariacel 165/ICI Surfactants	1.00
	Cyclomethicone	Dow Corning 344 Fluid/Dow Corning	5.00
20	Glyceryl Stearate		4.00
	Stearic Acid	Emersol 132, NF/Henkel	2.50
	Isostearyl Isostearate	Prisonne ISIS 2039/Unichema	10.00
	Hydrogenated Castor Oil	Castorwax/CasChem	2.00
	C <sub>12-15</sub> Alcohols Benzoate	Finsolv TN/Finetex	2.50
25	<b>Total</b>		<b>100.00</b>

## Procedure

30 Add Phase A ingredients to main vessel under impeller agitation. Heat phase A to 75-80°C. Combine Phase B ingredients; heat and mix to 85°C. Slowly add Phase B to batch; mix for 15 minutes at 85°C. Remove from heat; switch to paddle mixing and cool to room temperature.

35

- 27 -

## Formulation 4: Water/Oil Broad Spectrum Sunscreen Lotion

	INCI Name	Trade Name/Manufacturer	% w/w
	<b>Phase A-1</b>		
5	Octyl Methoxycinnamate	Eusolex® 2292/Rona	7.50
	Iso-amyl-alpha-acetyl-3-methoxy-4-hydroxy-cinnamate		5.00
	Octyl Stearate	Cetiol 868/Henkel	2.00
	Dicapryl Ether	Cetiol OE/Henkel	3.00
10	Cyclomethicone	Dow Corning 345 Fluid/Dow Corning	4.00
	Dimethicone	DC 200 fluid 50cST/Dow Corning	2.00
	PEG-30 Dipolyhydroxystearate	Ariacel P135/ICI	1.30
	Laurylmethicone copolyol	Dow Corning formulation Aid 5200/Dow	2.30
15	Behenamidopropyl dimethylamine Behenate	Catamol 220-B/Phoenix Chemical	0.50
	<b>Phase A-2</b>		
	Titanium Dioxide (and) Alumina (and) Simethicone	Eusolex® T-2000/Rona	8.00
20	Deionized Water		61.00 qs
	Propylene Glycol		2.00
	Sodium Chloride		0.80
	<b>Phase C</b>		
25	DMDM Hydantoin, Methylparaben, Propylparaben	Paragon II/McIntyre	0.60
	<b>Total</b>		<b>100.00</b>

## Procedure

30 Combine A-1; stir and heat to 55-60°C until all solids are dissolved. Disperse A-1 in A-1 by propeller agitation. Combine B; stir and heat to 50-55°C. Slowly add B to A while stirring vigorously. Add C to A/B; gently homogenize until mixture is uniform. Stir with anchor mixer allowing mixture to cool to room temperature.

35

- 28 -

## Formulation 5: UVA/UVB Sun Protection Cream with Avobenzone

INCI Name	Trade Name/Manufacturer	% w/w
<b>Phase A-1</b>		
Water (demineralized)		67.80
Disodium EDTA		0.05
Propylene glycol		3.00
Methylparaben		0.15
<b>Phase A-2</b>		
Carbomer	Carbopol Ultrez 10/BF Goodrich	0.20
<b>Phase B</b>		
Isopropyl Myristate		2.00
Cetyl Alcohol, Glyceryl Stearate, PEG-75 Stearate, Ceteth 20, Steareth 20	Emulium Delta/Gattefosse	4.00
Diethyl-3-methoxy-4-hydroxybenzylidene malonate		3.50
Homomethyl salicylate	Eusolex® HMS/Rona	7.00
Octyl salicylate	Eusolex® OS/Rona	7.00
Butyl methoxydibenzoylmethane	Eusolex® 9020/Rona	3.00
Dimethicone	Dow Corning Fluid 200, 100sct/Dow	1.00
C30-38 Olefin/Isopropyl Maleate/MA Copolymer	Performa V 1608/New Phase Technologies	1.00
<b>Phase C</b>		
Triethanolamine (99%)		0.30
<b>Phase D</b>		
preservatives		q.s.
<b>Total</b>		<b>100.00</b>

## 25 Procedure

Combine A-1; heat to 50EC while stirring until methylparaben is dissolved.  
 Disperse A-2 in A-1 with a sifter. Heat A to 65°C  
 Combine B; heat to 65-70°C while stirring until solids are dissolved.  
 Add B to A. Homogenize Add C at 55-60°C. Continue to homogenize  
 allowing mixture to cool to 40-45°C  
 Add D; stir with propeller mixer until uniform.  
 Adjust pH with TEA to 6.5-7.0

35

- 29 -

## Formulation 6: Oil/Water Sunscreen Lotion

INCI Name	Trade Name/Manufacturer	% w/w
<b>Phase A</b>		
Diisoamyl-3-methoxy-4-hydroxybenzylidene malonate		3.00
Isopropyl Myristate	Emerest 2314/Henkel	4.00
C12-15 Alkyl Benzoate	Finsolv TN/Finetex	4.00
Cetyl Alcohol	Crodacol C-70/Croda	1.50
Steareth- 2	Bnj 72/ICI Surfactants	2.00
Steareth- 21	Bnj 721/ICI Surfactants	2.50
Dimethicone	Dow Corning Fluid 200, 100sct/Dow	0.50
<b>Phase B</b>		
Deionized Water		81.07
Acrylates/C10-30 Alkyl Acrylates Crosspolymer	Carbopol ETD 2020/BF Goodrich	0.20
<b>Phase C</b>		
Triethanolamine (99%)	TEA 99% /Union Carbide	0.23
<b>Phase D</b>		
Phenoxyethanol (and) isopropylparaben (and)isobutylparaben (and) butylparaben	Liquapar PE/Sutton	1.00
<b>Total</b>		<b>100.00</b>

## Procedure

Prepare Phase B by dispersing Carbopol in water . Heat the dispersion to 70-75°C.

Combine Phase A ingredients. Stir and heat to 70-75°C.

Add Phase B to Phase A while stirring.

Add Phase C. Homogenize until mixture cools to 45-40°C.

Add Phase D. Stir allowing mixture to cool to room temperature.

- 30 -

## Formulation 7: Oil/Water Sunscreen Lotion

	INCI Name	Trade Name/Manufacturer	% w/w
	<b>Phase A</b>		
5	Avobenzene	Eusolex 9020/Rona	3.00
	Diisoamyl-3-methoxy-4-hydroxybenzylidene malonate		3.00
	Isopropyl Myristate	Emerest 2314/Henkel	4.00
	C12-15 Alkyl Benzoate	Finsolv TN/Finetex	4.00
	Cetyl Alcohol	Crodacol C-70/Croda	1.50
10	Steareth- 2	Bnj 72/ICI Surfactants	2.00
	Steareth- 21	Bnj 721/ICI Surfactants	2.50
	Dimethicone	Dow Corning Fluid 200, 100sct/Dow	0.50
	<b>Phase B</b>		
	Deionized Water		78.07
15	Acrylates/C10-30 Alkyl Acrylates Crosspolymer	Carbopol ETD 2020/BF Goodrich	0.20
	<b>Phase C</b>		
	Triethanolamine (99%)	TEA 99% /Union Carbide	0.23
	<b>Phase D</b>		
	Phenoxyethanol (and) isopropylparaben (and)isobutylparaben (and) butylparaben	Liquapar PE/Sutton	1.00
20	<b>Total</b>		<b>100.00</b>

## Procedure

- 25 Preprepare Phase B by dispersing Carbopol in water . Heat the dispersion to 70-75°C.
- Combine Phase A ingredients. Stir and heat to 70-75°C.
- Add Phase B to Phase A while stirring.
- Add Phase C. Homogenize until mixture cools to 45-40°C.
- Add Phase D. Stir allowing mixture to cool to room temperature.

30

35

## Formulation 8: Oil/Water Sunscreen Lotion

INCI Name	Trade Name/Manufacturer	% w/w
<b>Phase A</b>		
Avobenzone	Eusolex 9020/Rona	3.00
Disoamyl-3-methoxy-4-hydroxy-5-isopropyl benzylidene malonate		3.00
Isopropyl Myristate	Emerest 2314/Henkel	4.00
C12-15 Alkyl Benzoate	Finsolv TN/Finetex	4.00
Cetyl Alcohol	Crodacol C-70/Croda	1.50
Steareth- 2	Bnj 72/ICI Surfactants	2.00
Steareth- 21	Bnj 721/ICI Surfactants	2.50
Dimethicone	Dow Corning Fluid 200, 100sct/Dow	0.50
<b>Phase B</b>		
Deionized Water		78.07
Acrylates/C10-30 Alkyl Acrylates Crosspolymer	Carbopol ETD 2020/BF Goodrich	0.20
<b>Phase C</b>		
Triethanolamine (99%)	TEA 99% /Union Carbide	0.23
<b>Phase D</b>		
Phenoxyethanol (and) isopropylparaben (and)isobutylparaben (and) butylparaben	Liquapar PE/Sutton	1.00
<b>Total</b>		<b>100.00</b>

## Procedure

Preprepare Phase B by dispersing Carbopol in water. Heat the dispersion to 70-75°C.

Combine Phase A ingredients. Stir and heat to 70-75°C.

Add Phase B to Phase A while stirring.

Add Phase C. Homogenize until mixture cools to 45-40°C.

Add Phase D. Stir allowing mixture to cool to room temperature.



- 32 -

## Formulation 9: Oil/Water Sunscreen Lotion

INCI Name	Trade Name/Manufacturer	% w/w
<b>Phase A</b>		
Avobenzone	Eusolex 9020/Rona	3.00
Iso-amyl-alpha-acetyl-3-methoxy-4-hydroxy-5-isopropyl cinnamate		3.00
Isopropyl Myristate	Emerest 2314/Henkel	4.00
C12-15 Alkyl Benzoate	Finsolv TN/Finetex	4.00
Cetyl Alcohol	Crodacol C-70/Croda	1.50
Steareth- 2	Bnj 72/ICI Surfactants	2.00
Steareth- 21	Bnj 721/ICI Surfactants	2.50
Dimethicone	Dow Corning Fluid 200, 100sct/Dow	0.50
<b>Phase B</b>		
Deionized Water		78.07
Acrylates/C10-30 Alkyl Acrylates Crosspolymer	Carbopol ETD 2020/BF Goodrich	0.20
<b>Phase C</b>		
Triethanolamine (99%)	TEA 99% /Union Carbide	0.23
<b>Phase D</b>		
Phenoxyethanol (and) isopropylparaben (and)isobutylparaben (and) butylparaben	Liquapar PE/Sutton	1.00
<b>Total</b>		<b>100.00</b>

## Procedure

Preprepare Phase B by dispersing Carbopol in water. Heat the dispersion to 70-75°C.

Combine Phase A ingredients. Stir and heat to 70-75°C.

Add Phase B to Phase A while stirring.

Add Phase C. Homogenize until mixture cools to 45-40°C.

Add Phase D. Stir allowing mixture to cool to room temperature.

- 33 -

## FORMULATION 10

5	<u>Phase A</u>		<u>Phase B</u>
	Deionized water	60.0 %	Ethyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy cinnamate 8.75%
	Disodium EDTA	0.10 %	Octyl salicylate 5 %
	Glycerin	1.5 %	Aluminum stearate 5 %
	NaCl	3.0 %	Cyclomethicone/dimethicone 10 %
10	Butylene glycol	2.5 %	Cetyl dimethicone 1 %
			Cyclomethicone 2 %
			ABIC- EM 97 1 %
			Fragrance .15 %

## 15 Procedure

Combine phase B ingredients. Stir and heat to 70-75°C. Combine Phase A ingredients. Heat while stirring to 70-75°C. Add Phase B to Phase A while stirring. Add preservative. Stir, allowing mixture to cool to room temperature.

25

30

35

- 34 -

## Formulation 11: Sunscreen Oil/Water Spray Lotion

INCI Name	Trade Name (Supplier)	% w/w
<b>Phase A-1</b>		
Di-isopropyl-3,5-dimethoxy-4-hydroxybenzylidene malonate		7.50
Benzophenone-3	Eusolex® 4360 (Rona)	2.50
Dicapryl ether	Cetiol® OE (Henkel)	4.50
Dimethicone	Dow Corning 200®, 50 cst (Dow)	2.00
Stearyl Alcohol	Crodacol S-70 (Croda)	0.60
PPG-2 Ceteareth-9	Eumulgin® L (Henkel)	0.40
Steareth-10	Volpo 10 (Croda)	0.50
Glyceryl stearate, PEG-100 Stearate	Arlacel® 165 (ICI)	2.80
<b>Phase A-2</b>		
Titanium Dioxide, Simethicone, Alumina	Eusolex® T-2000 (Rona)	5.00
<b>Phase B-1</b>		
Demineralized water		66.10
Chitosan, water	Hydagen® CMF (Henkel)	2.00
Glycerin USP	Emery 916 (Henkel)	2.50
Dimethicone copolyol phosphate	Pecosil PS-100 (Phoenix Chemical)	2.50
<b>Phase B-2</b>		
Polyquaternium 37, Mineral oil, PPG-1 trideceth-6	Salcare SC 95 (Ciba)	0.40
<b>Phase C</b>		
Propylene Glycol, DMDM Hydantoin, Methylparaben, Propylparaben	Paragon™ II (McIntyre)	0.70
<b>Total</b>		<b>100.00</b>

## 25 Procedure

Combine A-1; stir and heat to 60 °C until all solids are dissolved. Disperse A-2 in A-1 with agitation. Combine B-1; stir and heat to 60 °C. Disperse B-2 in B-1 with agitation. Add A to B while stirring vigorously. gently homogenize allowing mixture to cool to 40 °C. Add C to A/B: gently homogenize until mixture is uniform. Stir with anchor mixer allowing to reach 25 °C prior to packaging. Use a high shear pump spray device for dispensing (e.g., Eurogel pump by Seaquist Perfect)

35

- 35 -

## Formulation 12: Sunscreen Cream

INCI Name	Trade Name/Manufacturer	% w/w
<b>Phase A</b>		
Deionized water		39.73
Carbomer (2% aq. solution)	Carbopol 980/BF Goodrich	15.00
Propylene Glycol		5.00
Methylparaben		0.20
Propylparaben		0.10
Triethanolamine (99%)		0.45
Tetrasodium EDTA		0.02
<b>Phase B</b>		
Octyl Methoxycinnamate	Eusolex® 2292/Rona	5.00
Benzophenone-3	Eusolex® 44360/Rona	3.00
Di-isoamyl-3,5-dimethoxy-4-hydroxybenzylidene malonate		4.50
Glyceryl Stearate (and) PEG-100 Stearate	Ariacel 165/ICI Surfactants	1.00
Cyclomethicone	Dow Corning 344 Fluid/Dow Corning	5.00
Glyceryl Stearate		4.00
Stearic Acid	Emersol 132, NF/Henkel	2.50
Isostearyl Isostearate	Prisonne ISIS 2039/Unichema	10.00
Hydrogenated Castor Oil	Castorwax/CasChem	2.00
C <sub>12-15</sub> Alcohols Benzoate	Finsolv TN/Finetex	2.50
<b>Total</b>		<b>100.00</b>

## Procedure

Add Phase A ingredients to main vessel under impeller agitation. Heat phase A to 75-80°C. Combine Phase B ingredients; heat and mix to 85°C. Slowly add Phase B to batch; mix for 15 minutes at 85°C. Remove from heat; switch to paddle mixing and cool to room temperature.

## Formulation 13: Water/Oil Broad Spectrum Sunscreen Lotion

	INCI Name	Trade Name/Manufacturer	% w/w
	<b>Phase A-1</b>		
5	Octyl Methoxycinnamate	Eusolex® 2292/Rona	7.50
	Iso-amyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy-cinnamate		5.00
	Octyl Stearate	Cetiol 868/Henkel	2.00
	Dicapryl Ether	Cetiol OE/Henkel	3.00
	Cyclomethicone	Dow Corning 345 Fluid/Dow Corning	4.00
10	Dimethicone	DC 200 fluid 50cST/Dow Corning	2.00
	PEG-30 Dipolyhydroxystearate	Ariacel P135/ICI	1.30
	Laurylmethicone copolyol	Dow Corning formulation Aid 5200/Dow	2.30
	Behenamidopropyl dimethylamine Behenate	Catamol 220-B/Phoenix Chemical	0.50
	<b>Phase A-2</b>		
15	Titanium Dioxide (and) Alumina (and) Simethicone	Eusolex® T-2000/Rona	8.00
	Deionized Water		61.00 qs
	Propylene Glycol		2.00
	Sodium Chloride		0.80
	<b>Phase C</b>		
20	DMDM Hydantoin, Methylparaben, Propylparaben	Paragon II/McIntyre	0.60
	<b>Total</b>		<b>100.00</b>

## Procedure

- 25 Combine A-1; stir and heat to 55-60°C until all solids are dissolved. Disperse A-1 in A-1 by propeller agitation. Combine B; stir and heat to 50-55°C. Slowly add B to A while stirring vigorously. Add C to A/B; gently homogenize until mixture is uniform. Stir with anchor mixer allowing mixture to cool to room temperature.

30

35

- 37 -

## Formulation 14: UVA/UVB Sun Protection Cream with Avobenzone

INCI Name	Trade Name/Manufacturer	% w/w
<b>Phase A-1</b>		
Water (demineralized)		67.80
Disodium EDTA		0.05
Propylene glycol		3.00
Methylparaben		0.15
<b>Phase A-2</b>		
Carbomer	Carbopol Ultrez 10/BF Goodrich	0.20
<b>Phase B</b>		
Isopropyl Myristate		2.00
Cetyl Alcohol, Glyceryl Stearate, PEG-75 Stearate, Ceteth 20, Steareth 20	Emulium Delta/Gattefosse	4.00
Diethyl-3,5-dimethoxy-4-hydroxybenzylidene malonate		3.50
Homomethyl salicylate	Eusolex® HMS/Rona	7.00
Octyl salicylate	Eusolex® OS/Rona	7.00
Butyl methoxydibenzoylmethane	Eusolex® 9020/Rona	3.00
Dimethicone	Dow Corning Fluid 200, 100sct/Dow	1.00
C30-38 Olefin/Isopropyl Maleate/MA Copolymer	Performa V 1608/New Phase Technologies	1.00
<b>Phase C</b>		
Triethanolamine (99%)		0.30
<b>Phase D</b>		
preservatives		q.s.
<b>Total</b>		<b>100.00</b>

## 25 Procedure

Combine A-1; heat to 50°C while stirring until methylparaben is dissolved.  
 Disperse A-2 in A-1 with a sifter. Heat A to 65°C  
 Combine B; heat to 65-70°C while stirring until solids are dissolved.  
 Add B to A. Homogenize Add C at 55-60°C. Continue to homogenize  
 allowing mixture to cool to 40-45°C.  
 Add D; stir with propeller mixer until uniform.  
 Adjust pH with TEA to 6.5-7.0.

35

## Formulation 15: Oil/Water Sunscreen Lotion

INCI Name	Trade Name/Manufacturer	% w/w
<b>Phase A</b>		
Diisooamyl-3,5-dimethoxy-4-hydroxybenzylidene malonate		3.00
Isopropyl Myristate	Emerest 2314/Henkel	4.00
C12-15 Alkyl Benzoate	Finsolv TN/Finetex	4.00
Cetyl Alcohol	Crodacol C-70/Croda	1.50
Steareth- 2	Bnj 72/ICI Surfactants	2.00
Steareth- 21	Bnj 721/ICI Surfactants	2.50
Dimethicone	Dow Corning Fluid 200, 100sct/Dow	0.50
<b>Phase B</b>		
Deionized Water		81.07
Acrylates/C10-30 Alkyl Acrylates Crosspolymer	Carbopol ETD 2020/BF Goodrich	0.20
<b>Phase C</b>		
Triethanolamine (99%)	TEA 99% /Union Carbide	0.23
<b>Phase D</b>		
Phenoxyethanol (and) isopropylparaben (and) isobutylparaben (and) butylparaben	Liquapar PE/Sutton	1.00
<b>Total</b>		<b>100.00</b>

## Procedure

Prepare Phase B by dispersing Carbopol in water. Heat the dispersion to 70-75°C.

Combine Phase A ingredients. Stir and heat to 70-75°C.

Add Phase B to Phase A while stirring.

Add Phase C. Homogenize until mixture cools to 45-40°C.

Add Phase D. Stir allowing mixture to cool to room temperature.

## Formulation 16: Oil/Water Sunscreen Lotion

INCI Name	Trade Name/Manufacturer	% w/w
<b>Phase A</b>		
Avobenzone	Eusolex 9020/Rona	3.00
Diisooamyl-3,5-dimethoxy-4-hydroxy-benzylidene malonate		3.00
Isopropyl Myristate	Emerest 2314/Henkel	4.00
C12-15 Alkyl Benzoate	Finsolv TN/Finetex	4.00
Cetyl Alcohol	Crodacol C-70/Croda	1.50
Steareth- 2	Bnj 72/ICI Surfactants	2.00
Steareth- 21	Bnj 721/ICI Surfactants	2.50
Dimethicone	Dow Corning Fluid 200, 100sct/Dow	0.50
<b>Phase B</b>		
Deionized Water		78.07
Acrylates/C10-30 Alkyl Acrylates Crosspolymer	Carbopol ETD 2020/BF Goodrich	0.20
<b>Phase C</b>		
Triethanolamine (99%)	TEA 99% /Union Carbide	0.23
<b>Phase D</b>		
Phenoxyethanol (and) isopropylparaben (and)isobutylparaben (and) butylparaben	Liquapar PE/Sutton	1.00
<b>Total</b>		<b>100.00</b>

## Procedure

Preprepare Phase B by dispersing Carbopol in water. Heat the dispersion to 70-75°C.

Combine Phase A ingredients. Stir and heat to 70-75°C.


Add Phase B to Phase A while stirring.

Add Phase C. Homogenize until mixture cools to 45-40°C.

Add Phase D. Stir allowing mixture to cool to room temperature.




Methods of preparation of two compounds of the invention are illustrated below.



It has been found that to provide antioxidant functionality, the phenyl group of the compounds of formula I should have a substituent patterns of "3,5-alkoxy-4-hydroxy or 3-alkoxy-4-hydroxy or 3-alkoxy-4-hydroxy-5-alkyl." Compounds of formula I also have a moiety, A, which provides UV absorbing functionality, (chromophoric in the UV range). Moiety A, can vary widely in structure with examples given in formulae II, III above.

The compounds of Formula I-IV, V and VI can be obtained by condensation of a corresponding 3, 5-dialkoxy, 4-hydroxy benzaldehyde of formula B,



- 41 -

wherein R is as defined above, with a compound that provides the UV absorbing moiety, "A" as defined above. An example is a compound of the formula:  $R^1-CH_2-C(O)XR^2$

wherein  $R^1$  and  $R^2$  and X are as defined above for formulae II-IV.

5

The benzaldehyde of formula B can be obtained commercially or prepared from 3, 4, 5-trimethoxybenzaldehyde through selective monodemethylation at the 4-position. This technique leads to syringaldehyde. Alternately, syringaldehyde can be prepared from 5-bromo-vanillin by replacing bromo-

10 group with methoxy ( or alkoxy or alkyl) using appropriate alcohol or activated alkyl functionality. The syringaldehyde or other aldehydes is then condensed with a compound to provide the desired UV absorbing moiety "A".

15

The entire disclosure of all applications, patents and publications, cited above are hereby incorporated by reference.

20

25

30

35

## EXAMPLES

### Example I: Ethyl- $\alpha$ -cyano-3-methoxy-4-hydroxy cinnamate

5        Condensation of vanillin with ethyl cyanoacetate in the presence of piperidine - acetic acid and benzene as the reaction medium at reflux temperature under continuous azeotropic water removal yields the title product. The reaction takes about 1.5 hours for completion. The yield obtained is typically 95%.

10

### Example II : Diethyl-3-methoxy-4-hydroxy benzylidene malonate

15        Condensation of 3-methoxy-4-hydroxy benzaldehyde (vanillin) with diethyl malonate in the presence of piperidine - acetic acid and benzene as the reaction medium at reflux temperature under continuous azeotropic water removal yields the title product. The reaction takes about 6.5 hours for completion.

### Example III: Ethyl- $\alpha$ -acetyl-3-methoxy-4-hydroxy-cinnamate

20

Condensation of 3-methoxy-4-hydroxy benzaldehyde (vanillin) with ethyl acetoacetate in the presence of piperidine - acetic acid and benzene as the reaction medium at reflux temperature yields the title product. The reaction takes about 3.5 hours for completion.

25

### Example IV: Di-(2-Ethylhexyl)-3-methoxy-4-hydroxy benzylidene malonate

30        Transesterification of diethyl malonate using 2-ethylhexyl alcohol in neat condition at 140-155°C for 2 hours under nitrogen blanketing in the presence of sulfuric acid and after work up, followed by high vacuum distillation, yields di-6-ethylhexyl malonate.

35        Condensation of 3-methoxy-4-hydroxy benzaldehyde (vanillin) with di-2-ethylhexyl malonate in the presence of piperidine - acetic acid and benzene as the reaction medium at reflux temperature under continuous

azeotropic water removal yields di-2-ethylhexyl-3-methoxy-4-hydroxy benzylidene malonate. The reaction takes about nine hours for completion. The yield typically obtained is 91%.

Example V: Di-isoamyl-3-methoxy-4-hydroxy benzylidene malonate

5

Example IV is repeated, except in the condensation step, di-2-ethylhexyl malonate is replaced with di-isoamyl malonate. The yield typically obtained is over 90%.

10

Example VI: Di-isopropyl-3-ethoxy-4-hydroxy benzylidene malonate

Example IV is repeated, except in the condensation step, di-2-ethylhexyl malonate is replaced with di-isopropyl malonate. The yield typically obtained is over 90%.

15

Example VII: Di-dodecyl-3-methoxy-4-hydroxy benzylidene malonate

Example IV is repeated, except in the condensation step, di-2-ethylhexyl malonate is replaced with di-dodecyl malonate. The yield typically obtained is over 90%.

20

Example VIII: Iso-propyl-alpha-acetyl-3-methoxy-4-hydroxy-cinnamate

Example III is repeated, except in the condensation step, ethyl acetoacetate is replaced with iso-propyl acetoacetate. The yield of the desired product is 88%.

25

Example IX: Iso-butyl-alpha-acetyl-3-methoxy-4-hydroxy-cinnamate

Example III is repeated, except in the condensation step, ethylacetoacetate is replaced with iso-butyl-acetoacetate. The yield of the desired product is 89%.

30

Example X: Iso-amyl-alpha-acetyl-3-methoxy-4-hydroxy-cinnamate

35

- 44 -

Example III is repeated, except in the condensation step, ethylacetoacetate is replaced with iso-amyl acetoacetate. The yield of the desired product is 89%.

5      Example XI: Disoamyl-3-methoxy-4-hydroxy-5-isopropyl benzylidene malonate

10      Condensation of 3-methoxy-4-hydroxy-5-isopropyl benzaldehyde with di-isoamyl malonate in the presence of piperidine-acetic acid and benzene as the reaction medium at reflux temperature under continuous azeotropic water removal yields the title product. The reaction takes about 3 hours for completion. The yield obtained is typically 90-95%.

15      Example XII: Isoamyl-alpha-acetyl-3-methoxy-4-hydroxy-5-isopropyl-cinnamate

20      Condensation of 3-methoxy-4-hydroxy-5-isopropyl benzaldehyde with isoamyl acetoacetate in the presence of piperidine-acetic acid and benzene as the reaction medium at reflux temperature under continuous azeotropic water removal yields the title product. The reaction takes about 4 hrs for completion. The yield obtained is typically 90-95%.

Example XIII: Ethyl-alpha-cyano-3,5-dimethoxy-4-hydroxy cinnamate

25      Monodemethylation of 3,4,5-trimethoxy benzaldehyde using sulphuric acid at 40°C. for 8 hours yields 3,5-Dimethoxy-4-hydroxy benzaldehyde (Syringaldehyde). Condensation of syringaldehyde with ethyl cyanoacetate in the presence of piperidine - acetic acid and benzene as the reaction medium at reflux temperature under continuous azeotropic water removal yields the title product. The reaction takes about 1.5 hours for completion.  
30      The yield obtained is typically 95%.

Example XIV: Diethyl-3,5-dimethoxy-4-hydroxy benzylidene malonate

35

- 45 -

Monodemethylation of 3,4,5-trimethoxy benzaldehyde using sulphuric acid at 40°C. for 8 hours as described above in Example 1 yields syringaldehyde.

5      Condensation of 3,5-Dimethoxy-4-hydroxy benzaldehyde (Syringaldehyde) with diethyl malonate in the presence of piperidine - acetic acid and benzene as the reaction medium at reflux temperature under continuous azeotropic water removal yields the title product. The reaction takes about 7.5 hours for completion.

10      Example XV: Ethyl-alpha-methyl-3,5-dimethoxy-4-hydroxy cinnamate

Monodemethylation of 3,4,5,-trimethoxy benzaldehyde using sulphuric acid at 40°C for 8 hours as described above in Example 1 yields syringaldehyde.

15      The Wittig salt is prepared by reaction of triphenyl phosphine and ethyl-2-bromopropionate in benzene media at 70-75°C for 8 hours and subsequent basification with 1N Sodium hydroxide to phenolphthalein end point at room temperature. Extraction with benzene, concentration of the benzene extract and the addition of petroleum ether (60-80°C) yield  
20      triphenyl methyl carbethoxy methylene phosphorane as a solid product. Condensation of 3,5-Dimethoxy-4-hydroxy benzaldehyde (Syringaldehyde) with triphenyl methyl carbethoxy methylene phosphorane is performed at reflux temperature in xylene for seven hours and after work up, yields the  
25      title compound.

25      Example XVI: Ethyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy-cinnamate

Monodemethylation of 3,4,5-trimethoxy benzaldehyde using sulphuric acid at 40°C for 8 hours as described above in Example 1 yields  
30      syringaldehyde.

Condensation of 3,5-Dimethoxy-4-hydroxy benzaldehyde (syringaldehyde) with ethyl acetoacetate in the presence of piperidine - acetic acid and benzene as the reaction medium at reflux temperature yields the title product. The reaction takes about 3.5 hours for completion.

35

Example XVII: Di-(2-Ethylhexyl)-3,5-dimethoxy-4-hydroxy benzylidene malonate

Monodemethylation of 3,4,5-trimethoxy benzaldehyde using sulphuric acid at 40°C for 8 hours as described above in Example 1 yields syringaldehyde.

Transesterification of diethyl malonate using 2-ethylhexyl alcohol in neat condition at 140-155°C for 2 hours under nitrogen blanketing in the presence of sulphuric acid and after work up, followed by high vacuum distillation, yields di-6-ethylhexyl malonate.

Condensation of 3,5-Dimethoxy-4-hydroxy benzaldehyde (Syringaldehyde) with di-2-ethylhexyl malonate in the presence of piperidine - acetic acid and benzene as the reaction medium at reflux temperature under continuous azeotropic water removal yields di-2-ethylhexyl-3,5-dimethoxy-4-hydroxy benzylidene malonate. The reaction takes about nine hours for completion. The yield typically obtained is 91%.

Example XVIII: Di-isoamyl-3,5-dimethoxy-4-hydroxy benzylidene malonate

Example VI was repeated, except in the condensation step, di-2-ethylhexyl malonate was replaced with di-isoamyl malonate. The yield typically obtained was over 90%.

Example XIX: Di-isopropyl-3,5-dimethoxy-4-hydroxy benzylidene malonate

Example VI was repeated, except in the condensation step, di-2-ethylhexyl malonate was replaced with di-isopropyl malonate. The yield typically obtained was over 90%.

Example XX: Di-dodecyl-3,5-dimethoxy-4-hydroxy benzylidene malonate

Example VI was repeated, except in the condensation step, di-2-ethylhexyl malonate was replaced with di-dodecyl malonate. The yield typically obtained was over 90%.

Example XXI: Iso-propyl-alpha-acetyl-3,5-diimethoxy-4-hydroxy-cinnamate

- 47 -

Example IV was repeated, except in the condensation step, ethyl acetoacetate was replaced with iso-propyl acetoacetate. The yield of the desired product was 88%.

Example XXII: Iso-butyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy-cinnamate

5

Example IV was repeated, except in the condensation step, ethylacetoacetate was replaced with iso-butyl-acetoacetate. The yield of the desired product was 89%.

10

Example XXIII: Iso-amyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy-cinnamate

Example IV was repeated, except in the condensation step, ethylacetoacetate was replaced with iso-amyl acetoacetate. The yield of the desired product was 89%.

15

Comparative Example A : Ethyl-alpha-cyano-3,4,5-trimethoxy cinnamate

20

Condensation of 3,4,5-trimethoxy benzaldehyde with ethyl cyanoacetate in the presence of piperidine - acetic acid and benzene as the reaction medium at reflux temperature under continuous azeotropic water removal yields the title product. The reaction takes about three hours for completion and the yield obtained is typically 90%.

Comparative Example B: Diethyl-3,4,5-trimethoxy benzylidene malonate

25

Condensation of 3,4,5-trimethoxy benzaldehyde with diethyl malonate in the presence of piperidine - acetic acid and benzene as the reaction medium at reflux temperature under continuous azeotropic water removal yields the title product. The reaction takes about ten hours for completion. The yield obtained is typically 85%

30

35



### Antioxidant Activity by DPPH Test Method

A DPPH concentrate (2.5X) of 25mg of 1,1-Diphenyl-2-Picryl-Hydrazyl ACS# 1898-66-4 (Sigma #D-9132, lot 99H3601) dissolved in 250mL ethanol (USP), is prepared fresh on the measurement date. A DPPH working solution is then prepared by diluting 100mL of this concentrate to a final volume of 250mL (100  $\Phi$ M/mL). A blank 13x100mm borosilicate glass screw top tube of ethanol (USP) is used to zero the spectrometer (Milton Roy, Spectronic 20+) at 517 nm and a control tube of DPPH working solution is measured under identical conditions, and taken as 0% activity. Aliquots of the 0.25% & 0.5% (RT & 45EC) test solution are added to tubes followed by the rapid addition of 4mL DPPH working solution then rapidly capped and mixed. After 20 minutes, the absorbance of each sample is read at 517 nm.

The percent reducing activity (%RA) is calculated using the following equation:

$$\% \text{ Reduction Activity} = \frac{100 A(0) - A(20)}{A(0)}$$

Where A(0) is the absorbance value of the DPPH working solution at 517nm zeroed against an ethanol blank and A(20) is the absorbance at 517nm, 20 minutes after combining the antioxidant with the DPPH working solution.

The concentration of antioxidant (mg/ml) in the final assay mixture is calculated based on the dilution of respective aliquots of each compound in the final assay volume and %RA tabulated and plotted as percent activity at each concentration in the dilution series.

### Antioxidant Property

The antioxidant activity of selected compounds of this invention was determined from their reducing activity of a DPPH radical. Results of

selected compounds from this invention are summarized in the Tables 1 and 2.

Table 1: Antioxidant Activity of Vanillin-based Compounds of this Invention

Compounds	%Reducing Activity of DPPH Radical at 30 µg/ml	µg/ml Needed to Reduce 50% of DPPH radical (IC <sub>50</sub> )
Di-(2-ethylhexyl)-3-methoxy-4-hydroxy benzylidene malonate	7.4	188
Di-isoamyl-3-methoxy-4-hydroxy benzylidene malonate	9.5	172
Isoamyl-alpha-acetyl-3-methoxy-4-hydroxy cinnamate	22	72
Di-(2-ethylhexyl)-3-methoxy-4-hydroxy-5-isopropyl-benzylidene malonate	11.2	161
Isoamyl-alpha-acetyl-3-methoxy-4-hydroxy-5-isopropyl cinnamate	28	68
Tinogard		46

Table 2 shows the antioxidant property of Syringaldehyde-based compounds (2/1, 2/2, 2/3, 2/4, 2/5, 2/7, 2/8 and 2/10).

<u>mg/ml</u>	<u>2/1</u>	<u>2/2</u>	<u>2/3</u>	<u>2/4</u>	<u>2/5</u>	<u>2/7</u>	<u>2/8</u>	<u>2/10</u>
2.500	0 0	3	25.40	71.70				
0.278			15.5	33.4	59.9	85.0	33.7	30.1
0.139			11.3	29.51	47.3	77.3	23.2	22.3
0.056			8.4	12.8	31.0	61.2	13.0	14.6
0.028			5.2	5.2	20.7	46.1	8.5	10.2
2/1	diethyl-3,4,5-trimethoxy benzylidene malonate							
2/2	ethyl-alpha-cyano-3,4,5-trimethoxy cinnamate							
2/3	ethyl-alpha-cyano-3,5-dimethoxy-4-hydroxy cinnamate							
2/4	diethyl-3,5-dimethoxy-4-hydroxy benzylidene malonate							
2/5	ethyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy cinnamate							
2/7	ethyl-alpha-methyl-3,5-dimethoxy-4-hydroxy cinnamate							
2/8	di(2-ethyl-hexyl)-3,5-dimethoxy-4-hydroxy benzylidene malonate							
2/10	di-iso-amyl-3,5-dimethoxy-4-hydroxy benzylidene malonate							

35

- 50 -

Compounds with 3,5-dimethoxy-4-hydroxy substitution were found to exhibit much higher reducing activity (antioxidant activity) than compounds with 3,4,5-trimethoxy substitution. In order to boost antioxidant activity of the compounds of the present invention, other antioxidants can be combined. Some examples are those antioxidants mentioned above and Tocopherols, tocopherylacetate, Ascorbic acid, Emblica antioxidants, Proanthocyanidins (from pine bark, grape seed extract, and the like) green tea polyphenols, rosemary antioxidants, gallic acid, ellagic acid, butylhydroxy toluene (BHT), butylhydroxy anisole (BHA) and the like.

#### Photostability

The photostability of selected compounds (see Table 3 and 4) were tested according to the procedures below.

A solar simulator used for illumination of the samples in the experiments is constructed incorporating a 1kw Xe arc lamp, optical bench and sample illumination chamber. The lamp output is filtered through a water filter with a course window to remove most of the infrared radiation and optical filters to remove wavelengths below 290 nm. The output of the illumination system is focused onto the face of a 1 cm quartz Cuvette that is thermally equilibrated with a constant temperature water bath at 25°C. A magnetic stir is mounted under the Cuvette so that the samples could be stirred while being illuminated. An electric shutter is controlled by a dark room timer to provide precise control of illumination times. The solar simulator is constructed to provide illumination that closely matches terrestrial sunlight. The solar simulator delivers roughly 250 J/cm<sup>2</sup> over a 2-hour period of illumination in a 290-490 nm range. This irradiance is determined using two nitrobenzaldehyde chemical actinometry. The irradiance is much higher than other solar simulator systems which typically illuminate a large area in order to illuminate many samples simultaneously rather than being focused down to a very small area.

Each sunscreen compound is dissolved in 70% ethanol/30% water and the UV visible absorption spectrum measured with a Shimadzu UV 2101-double beam spectrophotometer using the solvent as reference. A control solution of Octocrylene is prepared and the UV-visible absorption spectrum measured. Each solution is then illuminated for two hours in the solar simulator. After illumination, the absorption spectrum is again measured for each solution.

As Table 3 and 4 illustrate, the tested compounds were found to be photostable after two hours of illumination in a Xe-arc solar simulator. This data shows compounds of this invention have comparable photostabilities to Octocrylene under the experimental conditions employed.

Photostability of the individual compounds is determined by differential UV-absorption spectra before and after illumination. % Loss of absorption, hence the loss of individual compound, is calculated from the reduction in optical density after illumination. Likewise, stabilization of Avobenzone in the presence of individual compounds of this invention was also calculated.

Table 3: Results of Photostability of Vanillin-Based Compounds of this Invention & their Stabilization to Avobenzone (in solution)

Compound	$\lambda_{\max}$ , nm (Ethanol)	Photostability % Loss in 2 hrs	Stabilization of Avobenzone <sup>2</sup> % Loss of Avobenzone in 2 hrs
Di-(2-ethylhexyl)-3-methoxy-4-hydroxy benzylidene malonate	332	1	4.5
Di-isoamyl-3-methoxy-4-hydroxy benzylidene malonate	333	3.2	3.8
Isoamyl- $\alpha$ -acetyl-3-methoxy-4-hydroxy cinnamate	339	4.1	Insignificant
Di-(2-ethylhexyl)-3-methoxy-4-hydroxy-5-isopropyl-benzylidene malonate	334	2	2.5
Isoamyl- $\alpha$ -acetyl-3-methoxy-4-hydroxy-5-isopropyl cinnamate	341	3.2	Insignificant

- 52 -

Avobenzene	358	37	
Octocrylene (control)	303	2.8	1.5

<sup>1</sup>Solvent used 70% ethanol/30% water; solar simulator; about 250 J/cm<sup>2</sup>

<sup>2</sup>Product/Avobenzene (1:1, w/w); %Loss of Avobenzene by HPLC

5

All tested syringaldehyde-based compounds were found to be photostable after two hours of illumination in a Xe-arc solar simulator with the exception of two compounds 2/7. An examination of the UV-visible spectra (Table 4) reveals that the 2/1, 2/4, 2/5, 2/8, 2/10, 2/20, 2/22, 2/24 and 2/25

10

sunscreen compounds retain most of their absorptivity after 2 hours of illumination in the solar simulator while 2/7 degraded significantly (72% loss of absorbance) during this illumination period. The Octocrylene solution was found to exhibit a very little loss in absorptivity after 2 hours of illumination in the solar simulator. Thus 2/1, 2/4, 2/5, 2/8, 2/10, 2/20, 2/22, 2/24 and 2/25 have comparable photostabilities to Octocrylene under the experimental conditions employed.

15

Table 4: Results of Photostability of Syringaldehyde-Based Compounds of this Invention & their Stabilization to Avobenzene (in solution)

20

Compounds	Photostability Loss in 2 hrs <sup>1</sup>	Loss of Avobenzene in 2 hrs <sup>2</sup>
Diethyl-3,4,5-trimethoxy benzylidene malonate (2/1)	0%	No loss
Diethyl-3,5-dimethoxy-4-hydroxy benzylidene malonate (2/4)	3%	No loss
Ethyl- $\alpha$ -methyl-3,5-dimethoxy-4-hydroxy cinnamate (2/7)	72%	Not done
Di-isopropyl-3,5-dimethoxy-4-hydroxy benzylidene malonate (2/20)	1%	Not done
Di-isoamyl-3,5-dimethoxy-4-hydroxy benzylidene malonate (2/10)	4.1%	6%
Di-(2-ethylhexyl)-3,5-dimethoxy-4-hydroxy benzylidene malonate (2/8)	4.1% <sup>6</sup>	2%
Di-dodecyl-3,5-dimethoxy-4-hydroxy benzylidene malonate (2/24)	2%	19%
Ethyl- $\alpha$ -acetyl-3,5-dimethoxy-4-hydroxycinnamate (2/5)	1%	10%
Isoamyl- $\alpha$ -acetyl-3,5-dimethoxy-4-hydroxycinnamate (2/22)	4%	4%

25

30

35

- 53 -

Isobutyl-alpha-acetyl-3,5-dimethoxy-4-hydroxycinnamate (2/25)	5%	Not done
Avobenzone	37%	
Di-2-ethylhexyl-2,6-napthalene dicarboxylic acid (DENDA)	4%	6%
Octocrylene	5%	1.5%

<sup>1</sup> Solvent used 70% ethanol / 30% water; solar simulator; about 250 J/cm<sup>2</sup>, % product loss

<sup>2</sup> Product / Avobenzone (1:1, w/w); % Loss of Avobenzone by HPLC

### Stabilizing Activity

The stabilizing activity of selected compounds (2/1, 2/4, 2/5, 2/8, 2/10, 2/22, 2/24) toward Avobenzone was tested and compared with a conventional product according to the procedures below.

Individual solutions of selected sunscreen compounds (2/1, 2/4, 2/5, 2/8, 2/10, 2/22, 2/24) with Avobenzone were as follows. Each sunscreen compound was dissolved in 70% ethanol/30% H<sub>2</sub>O solution containing roughly an equal molar amount of Avobenzone. A similar solution containing Di-2-ethylhexyl-2,6-napthalene dicarboxylic acid (DENDA) or octocrylene and Avobenzone were also prepared. Each solution was then illuminated in the solar simulator as configured above for the photostability tests and aliquots of each solution were removed at 30-minute time intervals. These aliquots were injected into an HPLC and the loss of Avobenzone was followed with illumination time. The high performance liquid chromatograph (HPLC) used for all experiments reported therein incorporated a Spectra-Physics model P-200 pump with an Applied Biosystems model 785A UV-Visible detector with a Rheodyne manual injector incorporating a 50 ml sample loop and a 150 x 4.6 mm reversed-phase C<sub>18</sub> column (Alltech). All analyses were carried out under isocratic elution conditions using CH<sub>3</sub>OH/H<sub>2</sub>O mixtures for the mobile phase at a flow rate of 1 H<sub>2</sub>O ml per minute. It was necessary to employ HPLC separation of Avobenzone from each of the sunscreen compounds to quantify Avobenzone due to the absorption spectra overlap with some of these compounds. Results are shown in the Table 4.

- 54 -

The loss of Avobenzene when illuminated alone in solution was rapid exhibiting a half life of approximately 3 hours in the solar simulator. Figs. 3 and 4 reveal that the sunscreen compounds appear to stabilize Avobenzene as effectively as DENDA antioxidant. The loss of Avobenzene in the presence of DENDA was found to follow unusual kinetics. Initially the loss of Avobenzene was quite rapid but then seemed to become stable.

The UV-spectral study of the present inventive compounds shows that they have broad absorption bands that extend across the UV region. They exhibit lower molar absorption than Avobenzene but have much better photostability than Avobenzene. General data regarding the absorbance characteristics of the sunscreen compounds and Avobenzene are presented in Table 5.

Table 5: Absorbance and molar absorptivity data for sunscreen compounds measured in 70% ethanol/30% H<sub>2</sub>O solution

	Compound	$\lambda_{\text{Max}}$	$\lambda_{\text{Max}}(\text{M}^{-1}\text{cm}^{-1})$
20	Avobenzene	360 nm	$2.5 \times 10^4$
	Diethyl,3,4,5-trimethoxy benzylidene malonate (2/1)	313 nm	$2.0 \times 10^4$
25	Ethyl-alpha-cyano 3,4,5- trimethoxy cinnamte (2/4)	338 nm	$1.2 \times 10^4$
	Ethyl-alpha-aceryl 3,5,- dimethoxy-4-hydroxy cinnamte (2/5)	348 nm	$1.9 \times 10^4$
30	Ethyl-alpha-methyl 3,5- dimethoxy-4-hydroxy cinnamte (2/7)	314 nm	N/A
35	Di-(2-ethylhexyl)-3,5- dimethoxy-4-hydroxy benzylidene malonate (2/8)	340 nm	$1.6 \times 10^4$

Photostabilization of avobenzene in formulations under UV B light

5 Surprisingly, we have found that photostabilization of Avobenzene with compounds of present invention is much superior to commercially available photostabilizer (DENDA or TQ). Thus three formulations have been tested for Avobenzene photostability : Avobenzene (2%), Avobenzene + 2/8 (2%:2%, [di-(2-ethylhexyl)3,5-dimethoxy-benzylidene malonate]) and Avobenzene + TQ (2%:2%). Tests were performed by  
10 obtaining a thick product films between 2 glass slides and then irradiated for 8 h (about 16 MED, 8mJ/Cm<sup>2</sup>) under UV B light. A small amount of product is then re-dissolved in Ethanol:water (70%:30%) and the maximum absorbance measured. % residual Avebenzone was calculated by differential UV spectra. Result is summarized in the Table 6.

15

Table 6: Stabilization of avobenzene in formulated products

20

Formulated Products	Intitial Avobenzene	Avobenzene left after 8 hr of UV-B irradiation
Avobenzene	100%	27%
Avobenzene+ 2/8	100%	81%
Avobenzene + TQ	100%	21%

Photostabilization of Avobenzene (2%) in formulation under UV B irradiation at various ratios of photostabilizer (2-6%): 2/8, TQ and OCR

25 For better visualization of the long-term photostabilization effects of 2/8 [di-(2-ethylhexyl)3,5-dimethoxy-benzylidene malonate], samples have been tested by measuring the transmission spectra. From these spectra, absorption at 358 nm was corrected for light scattering and overlapping  
30 absorption bands. The relative loss of avobenzene is calculated from the relative decrease in this absorption band. Results are summarized in the Table 7.

35



Table 7: Stabilization of avobenzene in formulated products with different ratios of stabilizers


Formulated Products	Intitial Avobenzene	Avobenzene left after 8 hr of UV-B irradiation
Avobenzene	100%	27%
Avobenzene+ 2/8 (2%/2%)	100%	81%
Avobenzene+ 2/8 (2%/4%)	100%	84%
Avobenzene+ 2/8 (2%/6%)	100%	94%
Avobenzene+ TQ (2%/2%)	100%	21%
Avobenzene+ TQ (2%/4%)	100%	27%
Avobenzene + TQ (2%/6%)	100%	26%

The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the examples.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

**WHAT IS CLAIMED IS**

1. A compound of formula I




wherein

A is a moiety which is chromophoric within the UV radiation range of wavelengths to provide UV absorbing activity to the compound of formula I, wherein moiety A comprises two monovalent groups having carbonyl (C=O) functionality,

R<sup>6</sup> is independently linear or branched C<sub>1</sub>-C<sub>8</sub> alkyl, and  
R<sup>5</sup> is hydrogen or linear or branched C<sub>1</sub>-C<sub>8</sub> alkyl or linear or branched -O-C<sub>1-8</sub>-alkyl.

2. A compound of formula II



II

wherein

R<sup>1</sup> is selected from the group consisting of -C(O)CH<sub>3</sub>, -CO<sub>2</sub>R<sup>3</sup>, -C(O)NH<sub>2</sub> and -C(O)N(R<sup>4</sup>)<sub>2</sub>;

X is O or NH;

R<sup>2</sup> is linear or branched C<sub>1</sub> to C<sub>30</sub> alkyl;

R<sup>3</sup> is linear or branched C<sub>1</sub> to C<sub>20</sub> alkyl; and

- 58 -

each  $R^4$  is independently hydrogen, or linear or branched  $C_1$  to  $C_8$  alkyl;

$R^5$  is linear or branched  $C_1$ - $C_8$  alkyl or hydrogen, or linear or branched  $-O-C_{1-8}$  alkyl,  
and  $R^6$  is  $C_1$  to  $C_8$  alkyl.

5

3. A compound of claim 2 wherein  $R^6$  is  $C_1$ - $C_8$  alkyl, X is oxygen and  $R^2$  is linear or branched  $C_1$  to  $C_4$  alkyl.

10

4. A compound of at least one of the claims 2 or 3 wherein  $R^1$  is  $CO_2R^3$  and,  $R^3$  is linear or branched  $C_1$  to  $C_8$  alkyl preferably  $C_1$  to  $C_4$  alkyl.

15

5. A compound of at least one of the claims 2 to 4 wherein  $R^1$  is  $C(O)CH_3$ .

6. A compound of at least one of the claims 2 or 3 wherein  $R^1$  is  $-C(O)N(R^4)_2$ , and at least one  $R^4$  is hydrogen and the other is hydrogen or linear or branched  $C_1$  to  $C_4$  alkyl.

20

7. A compound of at least one of the claims 2 or 3 wherein  $R^1$  is  $-C(O)N(R^4)_2$ , and each  $R^4$  is independently linear or branched  $C_1$  to  $C_4$  alkyl.

25

8. A compound of claim 2 wherein  $R^6$  is  $C_1$ - $C_4$  alkyl,  $R^1$  is  $-CO_2R^3$ , and at least one of  $R^2$  and  $R^3$  is linear or branched  $C_8$  to  $C_{20}$  alkyl.

30


9. A compound of claim 8 wherein  $R^2$  and  $R^3$  are each linear or branched  $C_8$ - $C_{12}$  alkyl.

10. A compound of claim 8 wherein at least one of  $R^2$  and  $R^3$  is linear or branched  $C_{12}$  to  $C_{20}$  alkyl.

35

11. A compound of at least one of the claims 1 to 10 wherein  $R^6$  is methyl or ethyl.

12. A compound according to at least one of the claims 1 or 2, wherein the compound is one of the formulae III or IV



wherein

$R^1$  is selected from the group consisting  $-C(O)CH_3$ ,  $-CO_2$  ( $C_1$ - $C_8$  alkyl),  $-C(O)NH_2$  and  $-C(O)N(C_1-C_4 \text{ alkyl})_2$ ;

X is O or NH; and

$R^2$  is  $C_1$ - $C_{12}$  alkyl, and

$R^5$  is  $C_1$ - $C_8$  linear or branched alkyl or  $-O$ -  $C_{1-8}$  linear or branched alkyl.

13. A compound of claim 12 wherein X is oxygen and  $R^2$  is linear or branched  $C_1$  to  $C_4$  alkyl and  $R^1$  is  $-CO_2C_8H_{18}$ .

14. A compound of at least one of the claims 1 to 13, wherein  $-O-R^6$  and  $-R^5$  are identical, and preferably  $R^5$  is  $-O$ -Methyl and  $-O$ -Ethyl and  $R^6$  is  $-Methyl$  or  $-Ethyl$ .

15. A compound of claim 1 selected from the group consisting of ethyl-  $\alpha$ - cyano-3-methoxy- 4-hydroxy cinnamate, ethyl-  $\alpha$ - acetyl-3-methoxy- 4-hydroxy cinnamate, iso-propyl- $\alpha$ -acetyl-3-methoxy-4-hydroxy cinnamate, iso-amyl- $\alpha$ -acetyl-3-methoxy-4-hydroxy cinnamate, 2-ethylhexyl- $\alpha$ -acetyl-3-methoxy-4-hydroxy cinnamate, diethyl-3-methoxy- 4-hydroxy benzylidene malonate, di-(2-ethylhexyl)-3-methoxy- 4-hydroxy benzylidene malonate, diisoamyl-3-methoxy-4-hydroxy benzylidene malonate, dipalmitoyl-3-methoxy-4-hydroxy benzylidene malonate, di-dodecyl-3-methoxy-4-hydroxy benzylidene malonate, di-isopropyl-3-methoxy-4-hydroxy benzylidene malonate,

- 60 -

- di-(2-ethylhexyl)-3-methoxy-4-hydroxy-5-isopropyl-benzylidene malonate,  
 di-isoamyl-3-methoxy-4-hydroxy-5-tert.butyl-benzylidene malonate,  
 iso-amyl-alpha-acetyl-3-methoxy-4-hydroxy-5-isopropyl cinnamate,  
 iso-amyl-alpha-acetyl-3-methoxy-4-hydroxy-5-tert.butyl cinnamate,  
 5 ethyl- alpha- cyano-3, 5-dimethoxy- 4-hydroxy cinnamate,  
 ethyl- alpha- acetyl-3, 5-dimethoxy- 4-hydroxy cinnamate,  
 iso-propyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy cinnamate,  
 iso-amyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy cinnamate,  
 2-ethylhexyl-alpha-acetyl-3,5-dimethoxy-4-hydroxy cinnamate,  
 10 diethyl-3, 5-dimethoxy- 4-hydroxy benzylidene malonate,  
 di-(2-ethylhexyl)-3,5-dimethoxy- 4-hydroxy benzylidene malonate,  
 diisoamyl-3, 5-dimethoxy-4-hydroxy benzylidene malonate,  
 dipalmitoyl-3, 5-dimethoxy-4-hydroxy benzylidene malonate,  
 di-dodecyl-3,5-dimethoxy-4-hydroxy benzylidene malonate, and  
 15 di-isopropyl-3,5-dimethoxy-4-hydroxy benzylidene malonate.
16. A sunscreen formulation comprising a compound of at least one of claims 1 to 15 in an amount effective to absorb illumination in a range above 320 nm wavelength.
- 20 17. A sunscreen formulation comprising a compound of at least one of claims 1 to 15 in an amount effective to absorb illumination in a range of 290 to 400 nm wavelength.
- 25 18. A sunscreen formulation according to claim 16 or 17, which comprises from 0.1 to 40 wt.% of a compound of formula I defined in claim 1, and preferably comprising at least one additional organic sunscreen agent for filtering UV-B , UV-A rays or both and/or which comprises at least one inorganic metal oxide sunscreen agent.
- 30 19. Use of a compound according to at least one of claims 1 to 15 to stabilize at least one additional sunscreen agent against degradation from exposure to light.

- 61 -

- 5 20. A personal care formulation that comprises a compound according to at least one of claims 1 to 15 in an amount effective to absorb illumination in a range above 320 nm wavelength, a cosmetically acceptable carrier and at least one cosmetic adjuvant selected from the group consisting of preservatives, antifoams, perfumes, oils, waxes, propellants, dyes, pigments, waterproofing agents, emulsifiers, surfactants, thickeners, humectants, exfoliants and emollients.
- 10 21. A method of protecting a substrate from UV radiation which comprises applying a sunscreen formulation of at least one of claims 16 to 18 said substrate.
- 15 22. A method of improving the photostability of a sunscreen formulation said method comprising adding a compound according to at least one of claims 1 to 15 to said sunscreen formulation in an amount sufficient to improve the photostability of said sunscreen agent, amount of compound added preferably to the sunscreen formulation falls within the range of 0.1% to 40wt% of said sunscreen formulation.
- 20

25

30

35

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 02/06743

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K7/42 C07C69/618 C07C69/738 C07C255/41

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 28 16 819 A (BAYER AG) 31 October 1979 (1979-10-31)  claim 1; table I page 14, paragraph 2 -page 16, paragraph 5	1-4, 11, 15-18, 20, 21
X	US 5 830 441 A (CHAUDHURI RATAN K ET AL) 3 November 1998 (1998-11-03) cited in the application claim 1; example 4 column 4, line 53 -column 5, line 6	15-18, 20, 21
X	US 3 278 448 A (GUSTAV BUCHWALD ET AL) 11 October 1966 (1966-10-11) cited in the application claim 1 column 2, line 11 - line 13  -/--	1-3, 5, 11, 15

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

28 October 2002

Date of mailing of the international search report

15/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Krische, D

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/06743

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KNOEVENAGEL, E. ET AL.: CHEM. BER., vol. 37, 1904, pages 4476-4482, XP002218455 the whole document	1-5, 11, 15
X	SOHDA T ET AL: "Antiulcer activity of— 5-benzylthiazolidine-2,4-dione derivatives." CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 31, no. 2, February 1983 (1983-02), pages 560-569, XP002193484 ISSN: 0009-2363 table VI	1-4, 11, 15
X	CHO, H. ET AL.: J. MED. CHEM., vol. 34, 1991, pages 1503-1506, XP001109032 table 1, cpds 1,3-8	1, 2, 4
X	US 3 470 233 A (BOHN HANS-JOACHIM ET AL) 30 September 1969 (1969-09-30) examples 1,2	1-4, 11
X	WRIGHT M E ET AL: "ORGANIC NLO POLYMERS 2. A STUDY OF MAIN-CHAIN AND GUEST-HOST KAPPA(2) NLO POLYMERS: NLO-PHORE STRUCTURE VERSUS POLING" MACROMOLECULES, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 27, no. 11, 23 May 1994 (1994-05-23), pages 3009-3015, XP000445674 ISSN: 0024-9297 abstract scheme 1, cpd.9 page 3014	15
X	US 3 928 324 A (ROSATI ROBERT L) 23 December 1975 (1975-12-23) example VIII; table II	1
A	DATABASE WPI Section Ch, Week 198908 Derwent Publications Ltd., London, GB; Class D21, AN 1989-059208 XP002218456 & JP 01 013017 A (POLA KASEI KOGYO KK), 17 January 1989 (1989-01-17) abstract	12

-/--



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/06743

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GAZIT A ET AL: "TYRPHOSTINS I: SYNTHESIS AND BIOLOGICAL ACTIVITY OF PROTEIN TYROSINE KINASE INHIBITORS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 32, no. 19, 1989, pages 2344-2352, XP002048362 ISSN: 0022-2623 table I, cpd.4,15,16,23-25 table II, cpd.32,33,36 table III, cpd. 46,47,50-52	6,12
A	EP 0 631 177 A (FUJI PHOTO FILM CO LTD) 28 December 1994 (1994-12-28) page 10-11, cpd.II-10,11,18,19 page 5, line 18 - line 30	8
A	US 5 175 340 A (LANG GERARD ET AL) 29 December 1992 (1992-12-29) cited in the application claims 1,13	19,22

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 02/06743

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1,11,14,16-22 relate to an extremely large number of possible compounds, formulations containing them and uses thereof. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds, formulations and uses claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds of formula II, III and IV of claims 2 and 12 and the compounds of claim 15 and the formulations, uses and methods relating to these compounds.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/06743

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 2816819	A	31-10-1979	DE 2816819 A1	31-10-1979
			AT 363603 B	25-08-1981
			AT 284479 A	15-01-1981
			DE 2960522 D1	29-10-1981
			DK 156379 A	19-10-1979
			EP 0005182 A1	14-11-1979
			US 4284621 A	18-08-1981
US 5830441	A	03-11-1998	AU 2115199 A	02-08-1999
			WO 9936049 A1	22-07-1999
US 3278448	A	11-10-1966	NONE	
US 3470233	A	30-09-1969	DE 1274132 B	01-08-1968
			AT 261592 B	10-05-1968
			AT 261596 B	10-05-1968
			BE 666667 A	10-01-1966
			CH 508588 A	15-06-1971
			DE 1271720 B	04-07-1968
			DE 1245982 B	
			DE 1251335 B	
			DK 131903 B	22-09-1975
			FR 1447514 A	29-07-1966
			GB 1114426 A	22-05-1968
			NL 6508882 A	10-01-1966
US 3928324	A	23-12-1975	NONE	
JP 1013017	A	17-01-1989	JP 2552297 B2	06-11-1996
EP 0631177	A	28-12-1994	JP 7013299 A	17-01-1995
			EP 0631177 A1	28-12-1994
			US 5593818 A	14-01-1997
US 5175340	A	29-12-1992	LU 87271 A1	07-02-1990
			AT 74588 T	15-04-1992
			AU 622195 B2	02-04-1992
			AU 3793589 A	11-01-1990
			BR 8903372 A	13-02-1990
			DE 68901162 D1	14-05-1992
			EP 0350386 A1	10-01-1990
			JP 2059541 A	28-02-1990
			JP 2781415 B2	30-07-1998